JP2005523281A - アルファ−２−デルタリガンドとシクロオキシゲナーゼ−２の選択的阻害剤との組合せ - Google Patents
アルファ−２−デルタリガンドとシクロオキシゲナーゼ−２の選択的阻害剤との組合せ Download PDFInfo
- Publication number
- JP2005523281A JP2005523281A JP2003569193A JP2003569193A JP2005523281A JP 2005523281 A JP2005523281 A JP 2005523281A JP 2003569193 A JP2003569193 A JP 2003569193A JP 2003569193 A JP2003569193 A JP 2003569193A JP 2005523281 A JP2005523281 A JP 2005523281A
- Authority
- JP
- Japan
- Prior art keywords
- aminomethyl
- acetic acid
- alpha
- cyclopentyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 235
- 229940124639 Selective inhibitor Drugs 0.000 title abstract description 11
- 108010037462 Cyclooxygenase 2 Proteins 0.000 title description 3
- 102000010907 Cyclooxygenase 2 Human genes 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 253
- -1 1-aminomethyl-cyclohexylmethyl Chemical group 0.000 claims abstract description 137
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims abstract description 116
- 229960002004 valdecoxib Drugs 0.000 claims abstract description 111
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims abstract description 73
- 238000011282 treatment Methods 0.000 claims abstract description 66
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims abstract description 39
- 229960001233 pregabalin Drugs 0.000 claims abstract description 36
- 229960002870 gabapentin Drugs 0.000 claims abstract description 35
- UVUQVKDHNYUOJX-UHFFFAOYSA-N 2h-oxadiazol-5-one;hydrochloride Chemical compound Cl.O=C1C=NNO1 UVUQVKDHNYUOJX-UHFFFAOYSA-N 0.000 claims abstract description 34
- 208000002193 Pain Diseases 0.000 claims abstract description 34
- 206010007710 Cartilage injury Diseases 0.000 claims abstract description 30
- 230000036407 pain Effects 0.000 claims abstract description 30
- 230000004054 inflammatory process Effects 0.000 claims abstract description 23
- 206010061218 Inflammation Diseases 0.000 claims abstract description 21
- IUVMAUQEZFTTFB-YUMQZZPRSA-N Atagabalin Chemical compound C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C IUVMAUQEZFTTFB-YUMQZZPRSA-N 0.000 claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims description 193
- 125000000217 alkyl group Chemical group 0.000 claims description 61
- 125000004432 carbon atom Chemical group C* 0.000 claims description 52
- 241000124008 Mammalia Species 0.000 claims description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 239000001257 hydrogen Substances 0.000 claims description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 29
- 201000008482 osteoarthritis Diseases 0.000 claims description 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract description 45
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 abstract description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 34
- 201000010099 disease Diseases 0.000 abstract description 28
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 abstract description 16
- 229960000590 celecoxib Drugs 0.000 abstract description 14
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 abstract description 12
- 229960000371 rofecoxib Drugs 0.000 abstract description 10
- 206010003246 arthritis Diseases 0.000 abstract description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 230
- 238000000034 method Methods 0.000 description 106
- 239000002552 dosage form Substances 0.000 description 54
- 239000000203 mixture Substances 0.000 description 44
- 241001465754 Metazoa Species 0.000 description 33
- 229940111134 coxibs Drugs 0.000 description 29
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 28
- 230000005764 inhibitory process Effects 0.000 description 27
- 239000002253 acid Substances 0.000 description 26
- 238000009472 formulation Methods 0.000 description 26
- 238000012360 testing method Methods 0.000 description 26
- BIGWXAGEQONZGD-UHFFFAOYSA-N 2h-oxadiazol-5-one Chemical compound O=C1C=NNO1 BIGWXAGEQONZGD-UHFFFAOYSA-N 0.000 description 25
- 230000000694 effects Effects 0.000 description 25
- 239000000243 solution Substances 0.000 description 23
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 21
- 239000003826 tablet Substances 0.000 description 21
- 238000003556 assay Methods 0.000 description 20
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 19
- 239000003112 inhibitor Substances 0.000 description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 19
- 239000004480 active ingredient Substances 0.000 description 18
- 241000282472 Canis lupus familiaris Species 0.000 description 17
- 102000016611 Proteoglycans Human genes 0.000 description 17
- 108010067787 Proteoglycans Proteins 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 210000003141 lower extremity Anatomy 0.000 description 15
- 210000000845 cartilage Anatomy 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 13
- 239000002775 capsule Substances 0.000 description 13
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 13
- 239000003981 vehicle Substances 0.000 description 13
- 238000007792 addition Methods 0.000 description 12
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 229910052736 halogen Inorganic materials 0.000 description 11
- 125000005842 heteroatom Chemical group 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 241000282465 Canis Species 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 150000002367 halogens Chemical group 0.000 description 10
- 125000000623 heterocyclic group Chemical group 0.000 description 10
- 150000002431 hydrogen Chemical class 0.000 description 10
- 229910052760 oxygen Chemical group 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000002917 arthritic effect Effects 0.000 description 9
- 238000010170 biological method Methods 0.000 description 9
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 210000002414 leg Anatomy 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 8
- ONKWZNBXHSMMDK-UHFFFAOYSA-N 2-[2-(aminomethyl)-1,3,3a,4,5,6,7,7a-octahydroinden-2-yl]acetic acid Chemical compound C1CCCC2CC(CN)(CC(O)=O)CC21 ONKWZNBXHSMMDK-UHFFFAOYSA-N 0.000 description 7
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical group OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 208000037765 diseases and disorders Diseases 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 210000000629 knee joint Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 229940124530 sulfonamide Drugs 0.000 description 7
- 150000003456 sulfonamides Chemical group 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- GSBZRDSCOPXLJJ-UHFFFAOYSA-N 2-[2-(aminomethyl)-3,3a,4,5,6,6a-hexahydro-1h-pentalen-2-yl]acetic acid Chemical compound C1CCC2CC(CN)(CC(O)=O)CC21 GSBZRDSCOPXLJJ-UHFFFAOYSA-N 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 6
- 208000004454 Hyperalgesia Diseases 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000679 carrageenan Substances 0.000 description 6
- 229920001525 carrageenan Polymers 0.000 description 6
- 229940113118 carrageenan Drugs 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 230000036461 convulsion Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 230000003628 erosive effect Effects 0.000 description 6
- 210000001503 joint Anatomy 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 235000010981 methylcellulose Nutrition 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 6
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 6
- 229960004662 parecoxib Drugs 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002464 receptor antagonist Substances 0.000 description 6
- 229940044551 receptor antagonist Drugs 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 6
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical group C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 5
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 5
- 206010013935 Dysmenorrhoea Diseases 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 5
- 150000001408 amides Chemical group 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000000975 bioactive effect Effects 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 239000012154 double-distilled water Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 238000000099 in vitro assay Methods 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 4
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- UEQUKWNOOBRMOM-UHFFFAOYSA-N 2-[1-(aminomethyl)-3-methylcyclopentyl]-n-hydroxyacetamide Chemical compound CC1CCC(CN)(CC(=O)NO)C1 UEQUKWNOOBRMOM-UHFFFAOYSA-N 0.000 description 4
- JKONURJHZJCUAD-UHFFFAOYSA-N 2-[2-(aminomethyl)-3,3a,4,5,6,7,8,8a-octahydro-1h-azulen-2-yl]acetic acid Chemical compound C1CCCCC2CC(CN)(CC(O)=O)CC21 JKONURJHZJCUAD-UHFFFAOYSA-N 0.000 description 4
- HZROAXDCVPLQAB-UHFFFAOYSA-N 2-[3-(aminomethyl)-3-bicyclo[3.1.0]hexanyl]acetic acid Chemical compound C1C(CN)(CC(O)=O)CC2CC21 HZROAXDCVPLQAB-UHFFFAOYSA-N 0.000 description 4
- NDDZVQRQVFTNSN-UHFFFAOYSA-N 2-[3-(aminomethyl)-3-bicyclo[3.2.0]heptanyl]acetic acid Chemical compound C1C(CN)(CC(O)=O)CC2CCC21 NDDZVQRQVFTNSN-UHFFFAOYSA-N 0.000 description 4
- WYNCISGDELJLFS-UHFFFAOYSA-N 2h-oxadiazole-5-thione Chemical compound S=C1C=NNO1 WYNCISGDELJLFS-UHFFFAOYSA-N 0.000 description 4
- WQNPZZDMAFNGRO-UHFFFAOYSA-N 3-[[1-(aminomethyl)-3-methylcyclopentyl]methyl]-2h-1,2,4-thiadiazol-5-one Chemical compound C1C(C)CCC1(CN)CC1=NSC(=O)N1 WQNPZZDMAFNGRO-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 201000005569 Gout Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- FQUACWAUZNAVSB-UHFFFAOYSA-N [1-(aminomethyl)-3-methylcyclopentyl]methanesulfonamide Chemical compound CC1CCC(CN)(CS(N)(=O)=O)C1 FQUACWAUZNAVSB-UHFFFAOYSA-N 0.000 description 4
- LMIOCQWHTURATC-UHFFFAOYSA-N [1-(aminomethyl)-3-methylcyclopentyl]methanesulfonic acid Chemical compound CC1CCC(CN)(CS(O)(=O)=O)C1 LMIOCQWHTURATC-UHFFFAOYSA-N 0.000 description 4
- BMJBEIVJYIYDHJ-UHFFFAOYSA-N [1-(aminomethyl)-3-methylcyclopentyl]methylphosphonic acid Chemical compound CC1CCC(CN)(CP(O)(O)=O)C1 BMJBEIVJYIYDHJ-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000000674 adrenergic antagonist Substances 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- OZHLMLYAJHKVQM-UHFFFAOYSA-N n-[2-[1-(aminomethyl)-3-methylcyclopentyl]ethyl]-1,1,1-trifluoromethanesulfonamide Chemical compound CC1CCC(CN)(CCNS(=O)(=O)C(F)(F)F)C1 OZHLMLYAJHKVQM-UHFFFAOYSA-N 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000001301 oxygen Chemical group 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- ZOSAQGFXDPJQRE-UHFFFAOYSA-N 3-[2-(aminomethyl)-4-methylpentyl]-2h-1,2,4-oxadiazol-5-one;hydrochloride Chemical compound Cl.CC(C)CC(CN)CC1=NOC(=O)N1 ZOSAQGFXDPJQRE-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- 108010044467 Isoenzymes Proteins 0.000 description 3
- 208000003456 Juvenile Arthritis Diseases 0.000 description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 150000007514 bases Chemical class 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
- 229960001259 diclofenac Drugs 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 238000005462 in vivo assay Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- BHSGPLBWLQMWGF-UHFFFAOYSA-N n-[2-[1-(aminomethyl)-3-methylcyclopentyl]ethyl]methanesulfonamide Chemical compound CC1CCC(CN)(CCNS(C)(=O)=O)C1 BHSGPLBWLQMWGF-UHFFFAOYSA-N 0.000 description 3
- 229960002009 naproxen Drugs 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000005065 subchondral bone plate Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 2
- IASDTUBNBCYCJG-YUMQZZPRSA-N (3r,4s)-3-(azaniumylmethyl)-4,5-dimethylhexanoate Chemical compound CC(C)[C@H](C)[C@H](CN)CC(O)=O IASDTUBNBCYCJG-YUMQZZPRSA-N 0.000 description 2
- FEWJHICLKRAPHS-OCCSQVGLSA-N (3s,5r)-3-(aminomethyl)-5-methyl-7-phenylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCC1=CC=CC=C1 FEWJHICLKRAPHS-OCCSQVGLSA-N 0.000 description 2
- SIRQBZJUYVPMIC-SFYZADRCSA-N (3s,5r)-3-(aminomethyl)-5-methylheptanoic acid Chemical compound CC[C@@H](C)C[C@H](CN)CC(O)=O SIRQBZJUYVPMIC-SFYZADRCSA-N 0.000 description 2
- JBBFMHZVKGOWPT-YPMHNXCESA-N (3s,5s)-3-(aminomethyl)-5-methyl-6-phenylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CC1=CC=CC=C1 JBBFMHZVKGOWPT-YPMHNXCESA-N 0.000 description 2
- FMNQRUKVXAQEAZ-JNRFBPFXSA-N (5z,8s,9r,10e,12s)-9,12-dihydroxy-8-[(1s)-1-hydroxy-3-oxopropyl]heptadeca-5,10-dienoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@@H](O)[C@H]([C@@H](O)CC=O)C\C=C/CCCC(O)=O FMNQRUKVXAQEAZ-JNRFBPFXSA-N 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N 1-nonene Chemical group CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- JXSBZOVCVUSLIO-NQMVMOMDSA-N 2-[(1r,5r,6s)-6-(aminomethyl)-6-bicyclo[3.2.0]heptanyl]acetic acid Chemical compound C1CC[C@H]2[C@@](CN)(CC(O)=O)C[C@H]21 JXSBZOVCVUSLIO-NQMVMOMDSA-N 0.000 description 2
- BQOLBIIAWFGWEW-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,4-dimethylcyclopentyl]-n-hydroxyacetamide Chemical compound CC1CC(CN)(CC(=O)NO)CC1C BQOLBIIAWFGWEW-UHFFFAOYSA-N 0.000 description 2
- IUVMAUQEZFTTFB-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid Chemical compound CC1CC(CN)(CC(O)=O)CC1C IUVMAUQEZFTTFB-UHFFFAOYSA-N 0.000 description 2
- NBINUAYUYGRPPJ-UHFFFAOYSA-N 2-[3-(aminomethyl)-3-bicyclo[3.2.0]heptanyl]acetic acid;hydrochloride Chemical compound Cl.C1C(CN)(CC(O)=O)CC2CCC21 NBINUAYUYGRPPJ-UHFFFAOYSA-N 0.000 description 2
- RXDXEKHDLCVPDI-UHFFFAOYSA-N 3-[[1-(aminomethyl)-3,4-dimethylcyclopentyl]methyl]-2h-1,2,4-oxadiazole-5-thione Chemical compound C1C(C)C(C)CC1(CN)CC1=NOC(=S)N1 RXDXEKHDLCVPDI-UHFFFAOYSA-N 0.000 description 2
- NICKBMAOPZXAEJ-UHFFFAOYSA-N 3-[[1-(aminomethyl)-3,4-dimethylcyclopentyl]methyl]-2h-1,2,4-thiadiazol-5-one Chemical compound C1C(C)C(C)CC1(CN)CC1=NSC(=O)N1 NICKBMAOPZXAEJ-UHFFFAOYSA-N 0.000 description 2
- UAJKLVXISGSDMQ-UHFFFAOYSA-N 3-[[1-(aminomethyl)-3-methylcyclopentyl]methyl]-2h-1,2,4-oxadiazole-5-thione Chemical compound C1C(C)CCC1(CN)CC1=NOC(=S)N1 UAJKLVXISGSDMQ-UHFFFAOYSA-N 0.000 description 2
- CWSXPZYRFGYVBO-UHFFFAOYSA-N 4-methyl-2-(2h-tetrazol-5-ylmethyl)pentan-1-amine Chemical compound CC(C)CC(CN)CC1=NN=NN1 CWSXPZYRFGYVBO-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 0 CC(N1)=*OS1=O Chemical compound CC(N1)=*OS1=O 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- VWMFPMMAWJKGGU-UHFFFAOYSA-N [1-(aminomethyl)-3,4-dimethylcyclopentyl]methanesulfonamide Chemical compound CC1CC(CN)(CS(N)(=O)=O)CC1C VWMFPMMAWJKGGU-UHFFFAOYSA-N 0.000 description 2
- OQVYAGYPTAPIDD-UHFFFAOYSA-N [1-(aminomethyl)-3,4-dimethylcyclopentyl]methanesulfonic acid Chemical compound CC1CC(CN)(CS(O)(=O)=O)CC1C OQVYAGYPTAPIDD-UHFFFAOYSA-N 0.000 description 2
- DGYBGGKLAOGVTP-UHFFFAOYSA-N [1-(aminomethyl)-3,4-dimethylcyclopentyl]methylphosphonic acid Chemical compound CC1CC(CN)(CP(O)(O)=O)CC1C DGYBGGKLAOGVTP-UHFFFAOYSA-N 0.000 description 2
- QFLSQUNSWXMJBE-UHFFFAOYSA-N [1-(aminomethyl)cyclohexyl]methylphosphonic acid Chemical compound OP(=O)(O)CC1(CN)CCCCC1 QFLSQUNSWXMJBE-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 2
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002456 anti-arthritic effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 208000007474 aortic aneurysm Diseases 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 229940110331 bextra Drugs 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 239000003710 calcium ionophore Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000002327 cardiovascular agent Substances 0.000 description 2
- 229940125692 cardiovascular agent Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 125000006588 heterocycloalkylene group Chemical group 0.000 description 2
- 230000036732 histological change Effects 0.000 description 2
- 210000003035 hyaline cartilage Anatomy 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
- 229960004171 hydroxychloroquine Drugs 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000037231 joint health Effects 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- VCCMBMLHCPHYBL-UHFFFAOYSA-N n-[2-[1-(aminomethyl)-3,4-dimethylcyclopentyl]ethyl]-1,1,1-trifluoromethanesulfonamide Chemical compound CC1CC(CN)(CCNS(=O)(=O)C(F)(F)F)CC1C VCCMBMLHCPHYBL-UHFFFAOYSA-N 0.000 description 2
- MZLHDSAVPXLKBD-UHFFFAOYSA-N n-[2-[1-(aminomethyl)-3,4-dimethylcyclopentyl]ethyl]methanesulfonamide Chemical compound CC1CC(CN)(CCNS(C)(=O)=O)CC1C MZLHDSAVPXLKBD-UHFFFAOYSA-N 0.000 description 2
- PPIQMYQQPKTQBZ-UHFFFAOYSA-N n-[2-[1-(aminomethyl)cyclohexyl]ethyl]methanesulfonamide Chemical compound CS(=O)(=O)NCCC1(CN)CCCCC1 PPIQMYQQPKTQBZ-UHFFFAOYSA-N 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 229960001639 penicillamine Drugs 0.000 description 2
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000002089 prostaglandin antagonist Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 2
- 229960003329 sulfinpyrazone Drugs 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 201000004595 synovitis Diseases 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- CNHDIAIOKMXOLK-UHFFFAOYSA-N toluquinol Chemical compound CC1=CC(O)=CC=C1O CNHDIAIOKMXOLK-UHFFFAOYSA-N 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 229940029045 valdecoxib 20 mg Drugs 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 238000013389 whole blood assay Methods 0.000 description 2
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- IASDTUBNBCYCJG-SFYZADRCSA-N (3r,4r)-3-(azaniumylmethyl)-4,5-dimethylhexanoate Chemical compound CC(C)[C@@H](C)[C@H](CN)CC(O)=O IASDTUBNBCYCJG-SFYZADRCSA-N 0.000 description 1
- IZXYJQFRAQXPLJ-HLTSFMKQSA-N (3r,4r,5r)-3-(aminomethyl)-4,5-dimethylheptanoic acid Chemical compound CC[C@@H](C)[C@@H](C)[C@H](CN)CC(O)=O IZXYJQFRAQXPLJ-HLTSFMKQSA-N 0.000 description 1
- SXJRGKWBZUYFFU-BBBLOLIVSA-N (3r,4r,5r)-3-(aminomethyl)-4,5-dimethyloctanoic acid Chemical compound CCC[C@@H](C)[C@@H](C)[C@H](CN)CC(O)=O SXJRGKWBZUYFFU-BBBLOLIVSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- IASDTUBNBCYCJG-JGVFFNPUSA-N (3s,4s)-3-(aminomethyl)-4,5-dimethylhexanoic acid Chemical compound CC(C)[C@H](C)[C@@H](CN)CC(O)=O IASDTUBNBCYCJG-JGVFFNPUSA-N 0.000 description 1
- AGGHZWIPXQVUFK-OLZOCXBDSA-N (3s,5r)-3-(aminomethyl)-5,10-dimethylundecanoic acid Chemical compound CC(C)CCCC[C@@H](C)C[C@H](CN)CC(O)=O AGGHZWIPXQVUFK-OLZOCXBDSA-N 0.000 description 1
- BGQCKHBIIZKBJU-ZJUUUORDSA-N (3s,5r)-3-(aminomethyl)-5,7-dimethyloctanoic acid Chemical compound CC(C)C[C@@H](C)C[C@H](CN)CC(O)=O BGQCKHBIIZKBJU-ZJUUUORDSA-N 0.000 description 1
- CRENPLBKNGOMEN-MNOVXSKESA-N (3s,5r)-3-(aminomethyl)-5,8-dimethylnonanoic acid Chemical compound CC(C)CC[C@@H](C)C[C@H](CN)CC(O)=O CRENPLBKNGOMEN-MNOVXSKESA-N 0.000 description 1
- ADANSFWHWWMFDU-NEPJUHHUSA-N (3s,5r)-3-(aminomethyl)-5,9-dimethyldecanoic acid Chemical compound CC(C)CCC[C@@H](C)C[C@H](CN)CC(O)=O ADANSFWHWWMFDU-NEPJUHHUSA-N 0.000 description 1
- XKLLXPMHSPFOQW-HIFRSBDPSA-N (3s,5r)-3-(aminomethyl)-5-methyl-8-phenyloctanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCCC1=CC=CC=C1 XKLLXPMHSPFOQW-HIFRSBDPSA-N 0.000 description 1
- JETOEPZFEWLXBK-MNOVXSKESA-N (3s,5r)-3-(aminomethyl)-5-methyldecanoic acid Chemical compound CCCCC[C@@H](C)C[C@H](CN)CC(O)=O JETOEPZFEWLXBK-MNOVXSKESA-N 0.000 description 1
- IMLWGNYZSUWXIA-OLZOCXBDSA-N (3s,5r)-3-(aminomethyl)-5-methyldodecanoic acid Chemical compound CCCCCCC[C@@H](C)C[C@H](CN)CC(O)=O IMLWGNYZSUWXIA-OLZOCXBDSA-N 0.000 description 1
- LFUPHGVCYOENSK-ZJUUUORDSA-N (3s,5r)-3-(aminomethyl)-5-methylnon-8-enoic acid Chemical compound C=CCC[C@@H](C)C[C@H](CN)CC(O)=O LFUPHGVCYOENSK-ZJUUUORDSA-N 0.000 description 1
- KUSIIZRBOLFILF-ZJUUUORDSA-N (3s,5r)-3-(aminomethyl)-5-methylnonanoic acid Chemical compound CCCC[C@@H](C)C[C@H](CN)CC(O)=O KUSIIZRBOLFILF-ZJUUUORDSA-N 0.000 description 1
- YAMOPJPIJYQIGY-BDAKNGLRSA-N (3s,5r)-3-(aminomethyl)-5-methyloct-7-enoic acid Chemical compound C=CC[C@@H](C)C[C@H](CN)CC(O)=O YAMOPJPIJYQIGY-BDAKNGLRSA-N 0.000 description 1
- KKXFMWXZXDUYBF-BDAKNGLRSA-N (3s,5r)-3-(aminomethyl)-5-methyloctanoic acid Chemical compound CCC[C@@H](C)C[C@H](CN)CC(O)=O KKXFMWXZXDUYBF-BDAKNGLRSA-N 0.000 description 1
- HLRPRVFNTZZSHY-NEPJUHHUSA-N (3s,5r)-3-(aminomethyl)-5-methylundecanoic acid Chemical compound CCCCCC[C@@H](C)C[C@H](CN)CC(O)=O HLRPRVFNTZZSHY-NEPJUHHUSA-N 0.000 description 1
- SHMPJXGCBKABBT-KOLCDFICSA-N (3s,5r)-3-(aminomethyl)-6-cyclobutyl-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CC1CCC1 SHMPJXGCBKABBT-KOLCDFICSA-N 0.000 description 1
- LUHAQNAPMJQCNM-YPMHNXCESA-N (3s,5r)-3-(aminomethyl)-6-cyclohexyl-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CC1CCCCC1 LUHAQNAPMJQCNM-YPMHNXCESA-N 0.000 description 1
- SSFYNNBUYYSXPA-PWSUYJOCSA-N (3s,5r)-3-(aminomethyl)-6-cyclopentyl-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CC1CCCC1 SSFYNNBUYYSXPA-PWSUYJOCSA-N 0.000 description 1
- NOTGKXLKLLOOEU-SCZZXKLOSA-N (3s,5r)-3-(aminomethyl)-6-cyclopropyl-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CC1CC1 NOTGKXLKLLOOEU-SCZZXKLOSA-N 0.000 description 1
- SMNXTMSRSMKVKF-NEPJUHHUSA-N (3s,5r)-3-(aminomethyl)-7-(2-chlorophenyl)-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCC1=CC=CC=C1Cl SMNXTMSRSMKVKF-NEPJUHHUSA-N 0.000 description 1
- UHGGXBVJHJAACY-NEPJUHHUSA-N (3s,5r)-3-(aminomethyl)-7-(2-fluorophenyl)-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCC1=CC=CC=C1F UHGGXBVJHJAACY-NEPJUHHUSA-N 0.000 description 1
- VLOKSFBDWGOMMO-OLZOCXBDSA-N (3s,5r)-3-(aminomethyl)-7-(2-methoxyphenyl)-5-methylheptanoic acid Chemical compound COC1=CC=CC=C1CC[C@@H](C)C[C@H](CN)CC(O)=O VLOKSFBDWGOMMO-OLZOCXBDSA-N 0.000 description 1
- BCUGWHAHZHUTBT-YPMHNXCESA-N (3s,5r)-3-(aminomethyl)-7-(3-chlorophenyl)-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCC1=CC=CC(Cl)=C1 BCUGWHAHZHUTBT-YPMHNXCESA-N 0.000 description 1
- NIOLEXIXWFZQHF-YPMHNXCESA-N (3s,5r)-3-(aminomethyl)-7-(3-fluorophenyl)-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCC1=CC=CC(F)=C1 NIOLEXIXWFZQHF-YPMHNXCESA-N 0.000 description 1
- SNRGQBQIBPMKAD-OCCSQVGLSA-N (3s,5r)-3-(aminomethyl)-7-(3-methoxyphenyl)-5-methylheptanoic acid Chemical compound COC1=CC=CC(CC[C@@H](C)C[C@H](CN)CC(O)=O)=C1 SNRGQBQIBPMKAD-OCCSQVGLSA-N 0.000 description 1
- PEJUAJWTYKBIOI-YPMHNXCESA-N (3s,5r)-3-(aminomethyl)-7-(4-chlorophenyl)-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCC1=CC=C(Cl)C=C1 PEJUAJWTYKBIOI-YPMHNXCESA-N 0.000 description 1
- CBBMTFZOSNWURO-YPMHNXCESA-N (3s,5r)-3-(aminomethyl)-7-(4-fluorophenyl)-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCC1=CC=C(F)C=C1 CBBMTFZOSNWURO-YPMHNXCESA-N 0.000 description 1
- FLMJSJAQAYYKDH-OCCSQVGLSA-N (3s,5r)-3-(aminomethyl)-7-(4-methoxyphenyl)-5-methylheptanoic acid Chemical compound COC1=CC=C(CC[C@@H](C)C[C@H](CN)CC(O)=O)C=C1 FLMJSJAQAYYKDH-OCCSQVGLSA-N 0.000 description 1
- PMLSDYKLDFLDFE-PWSUYJOCSA-N (3s,5r)-3-(aminomethyl)-7-cyclobutyl-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCC1CCC1 PMLSDYKLDFLDFE-PWSUYJOCSA-N 0.000 description 1
- MUDLFVXEGNVOKP-OCCSQVGLSA-N (3s,5r)-3-(aminomethyl)-7-cyclohexyl-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCC1CCCCC1 MUDLFVXEGNVOKP-OCCSQVGLSA-N 0.000 description 1
- YBMHFGVRIJZSSK-YPMHNXCESA-N (3s,5r)-3-(aminomethyl)-7-cyclopentyl-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCC1CCCC1 YBMHFGVRIJZSSK-YPMHNXCESA-N 0.000 description 1
- SVXSTEONTBDCKH-KOLCDFICSA-N (3s,5r)-3-(aminomethyl)-7-cyclopropyl-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCC1CC1 SVXSTEONTBDCKH-KOLCDFICSA-N 0.000 description 1
- HOFQYLXJJCNSDJ-SFYZADRCSA-N (3s,5r)-3-(aminomethyl)-8,8,8-trifluoro-5-methyloctanoic acid Chemical compound FC(F)(F)CC[C@@H](C)C[C@H](CN)CC(O)=O HOFQYLXJJCNSDJ-SFYZADRCSA-N 0.000 description 1
- JHCIIQNMXAQHQC-YPMHNXCESA-N (3s,5r)-3-(aminomethyl)-8-cyclobutyl-5-methyloctanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCCC1CCC1 JHCIIQNMXAQHQC-YPMHNXCESA-N 0.000 description 1
- CREXEHWDFHWRIL-HIFRSBDPSA-N (3s,5r)-3-(aminomethyl)-8-cyclohexyl-5-methyloctanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCCC1CCCCC1 CREXEHWDFHWRIL-HIFRSBDPSA-N 0.000 description 1
- NMURPDGMDUUFIQ-OCCSQVGLSA-N (3s,5r)-3-(aminomethyl)-8-cyclopentyl-5-methyloctanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCCC1CCCC1 NMURPDGMDUUFIQ-OCCSQVGLSA-N 0.000 description 1
- DOHRVCLEAFTHHH-PWSUYJOCSA-N (3s,5r)-3-(aminomethyl)-8-cyclopropyl-5-methyloctanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCCC1CC1 DOHRVCLEAFTHHH-PWSUYJOCSA-N 0.000 description 1
- LGPVGEYDVBVKIW-BDAKNGLRSA-N (3s,5r)-3-(aminomethyl)-8-fluoro-5-methyloctanoic acid Chemical compound FCCC[C@@H](C)C[C@H](CN)CC(O)=O LGPVGEYDVBVKIW-BDAKNGLRSA-N 0.000 description 1
- RQZJZBKHCDLVEV-BDAKNGLRSA-N (3s,5r)-3-(aminomethyl)-8-hydroxy-5-methyloctanoic acid Chemical compound OCCC[C@@H](C)C[C@H](CN)CC(O)=O RQZJZBKHCDLVEV-BDAKNGLRSA-N 0.000 description 1
- IYMWWHAMHAYMGK-ZJUUUORDSA-N (3s,5r)-3-(aminomethyl)-9-fluoro-5-methylnonanoic acid Chemical compound FCCCC[C@@H](C)C[C@H](CN)CC(O)=O IYMWWHAMHAYMGK-ZJUUUORDSA-N 0.000 description 1
- LYHACJSMVUYWEN-IUCAKERBSA-N (3s,5s)-3-(aminomethyl)-5,6,6-trimethylheptanoic acid Chemical compound CC(C)(C)[C@@H](C)C[C@H](CN)CC(O)=O LYHACJSMVUYWEN-IUCAKERBSA-N 0.000 description 1
- RCSXHVBXPNZMAM-IUCAKERBSA-N (3s,5s)-3-(aminomethyl)-5,6-dimethylheptanoic acid Chemical compound CC(C)[C@@H](C)C[C@H](CN)CC(O)=O RCSXHVBXPNZMAM-IUCAKERBSA-N 0.000 description 1
- WFZVNCOAWKCUAL-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-(2-chlorophenoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)OC1=CC=CC=C1Cl WFZVNCOAWKCUAL-UWVGGRQHSA-N 0.000 description 1
- MYHCDXIFXKZNNJ-YUMQZZPRSA-N (3s,5s)-3-(aminomethyl)-5-(2-fluoroethoxy)hexanoic acid Chemical compound FCCO[C@@H](C)C[C@H](CN)CC(O)=O MYHCDXIFXKZNNJ-YUMQZZPRSA-N 0.000 description 1
- JHWOUEWSTXRSMC-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-(2-fluorophenoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)OC1=CC=CC=C1F JHWOUEWSTXRSMC-UWVGGRQHSA-N 0.000 description 1
- BNDAKBMXSSJUEC-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-5-(2-methoxyphenoxy)hexanoic acid Chemical compound COC1=CC=CC=C1O[C@@H](C)C[C@H](CN)CC(O)=O BNDAKBMXSSJUEC-QWRGUYRKSA-N 0.000 description 1
- XFVKCZVIDAAGDL-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-(2-nitrophenoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)OC1=CC=CC=C1[N+]([O-])=O XFVKCZVIDAAGDL-UWVGGRQHSA-N 0.000 description 1
- LUTANLWSGGTECK-YUMQZZPRSA-N (3s,5s)-3-(aminomethyl)-5-(3,3,3-trifluoropropoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)OCCC(F)(F)F LUTANLWSGGTECK-YUMQZZPRSA-N 0.000 description 1
- AKJUMQCGMWXTRU-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-(3-chlorophenoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)OC1=CC=CC(Cl)=C1 AKJUMQCGMWXTRU-UWVGGRQHSA-N 0.000 description 1
- CQARKITVLVJYGA-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-(3-fluorophenoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)OC1=CC=CC(F)=C1 CQARKITVLVJYGA-UWVGGRQHSA-N 0.000 description 1
- LCTKKGWISDWDSR-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-5-(3-methoxyphenoxy)hexanoic acid Chemical compound COC1=CC=CC(O[C@@H](C)C[C@H](CN)CC(O)=O)=C1 LCTKKGWISDWDSR-QWRGUYRKSA-N 0.000 description 1
- OGJYFMMWUJZBAA-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-(3-nitrophenoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)OC1=CC=CC([N+]([O-])=O)=C1 OGJYFMMWUJZBAA-UWVGGRQHSA-N 0.000 description 1
- NHOXILWDZJCMST-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-(4-chlorophenoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)OC1=CC=C(Cl)C=C1 NHOXILWDZJCMST-UWVGGRQHSA-N 0.000 description 1
- LNMPASBDSUFMIR-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-(4-fluorophenoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)OC1=CC=C(F)C=C1 LNMPASBDSUFMIR-UWVGGRQHSA-N 0.000 description 1
- YEQRFDBTIIEENH-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-5-(4-methoxyphenoxy)hexanoic acid Chemical compound COC1=CC=C(O[C@@H](C)C[C@H](CN)CC(O)=O)C=C1 YEQRFDBTIIEENH-QWRGUYRKSA-N 0.000 description 1
- JDDJTUPXDBEZQR-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-(4-nitrophenoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)OC1=CC=C([N+]([O-])=O)C=C1 JDDJTUPXDBEZQR-UWVGGRQHSA-N 0.000 description 1
- PNIDULZEBPPAHE-BQBZGAKWSA-N (3s,5s)-3-(aminomethyl)-5-(fluoromethoxy)hexanoic acid Chemical compound FCO[C@@H](C)C[C@H](CN)CC(O)=O PNIDULZEBPPAHE-BQBZGAKWSA-N 0.000 description 1
- XSZFKKIBBCFNRZ-IUCAKERBSA-N (3s,5s)-3-(aminomethyl)-5-[(2-methylpropan-2-yl)oxy]hexanoic acid Chemical compound CC(C)(C)O[C@@H](C)C[C@H](CN)CC(O)=O XSZFKKIBBCFNRZ-IUCAKERBSA-N 0.000 description 1
- NECOLRNJBIIURC-IUCAKERBSA-N (3s,5s)-3-(aminomethyl)-5-cyclobutylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)C1CCC1 NECOLRNJBIIURC-IUCAKERBSA-N 0.000 description 1
- QIVMNCBZDTZSSL-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-5-cyclohexylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)C1CCCCC1 QIVMNCBZDTZSSL-QWRGUYRKSA-N 0.000 description 1
- SCUJBZYQUHOYMH-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-cyclopentylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)C1CCCC1 SCUJBZYQUHOYMH-UWVGGRQHSA-N 0.000 description 1
- KPXGGTAOFKPJCB-YUMQZZPRSA-N (3s,5s)-3-(aminomethyl)-5-cyclopropylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)C1CC1 KPXGGTAOFKPJCB-YUMQZZPRSA-N 0.000 description 1
- JYZTVBQUSVRZIU-YUMQZZPRSA-N (3s,5s)-3-(aminomethyl)-5-ethoxyhexanoic acid Chemical compound CCO[C@@H](C)C[C@H](CN)CC(O)=O JYZTVBQUSVRZIU-YUMQZZPRSA-N 0.000 description 1
- ZXQGVLZCFOPLIL-BQBZGAKWSA-N (3s,5s)-3-(aminomethyl)-5-methoxyhexanoic acid Chemical compound CO[C@@H](C)C[C@H](CN)CC(O)=O ZXQGVLZCFOPLIL-BQBZGAKWSA-N 0.000 description 1
- UGDSFDKUWFNIQC-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-5-methyl-6-(2-nitrophenoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)COC1=CC=CC=C1[N+]([O-])=O UGDSFDKUWFNIQC-QWRGUYRKSA-N 0.000 description 1
- UMCMKOJZNISTMJ-IUCAKERBSA-N (3s,5s)-3-(aminomethyl)-5-methyl-6-(3,3,3-trifluoropropoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)COCCC(F)(F)F UMCMKOJZNISTMJ-IUCAKERBSA-N 0.000 description 1
- VEGDYCVGBXZOCI-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-5-methyl-6-(3-nitrophenoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)COC1=CC=CC([N+]([O-])=O)=C1 VEGDYCVGBXZOCI-QWRGUYRKSA-N 0.000 description 1
- CPDFDUUOZVLZJY-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-5-methyl-6-(4-nitrophenoxy)hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)COC1=CC=C([N+]([O-])=O)C=C1 CPDFDUUOZVLZJY-QWRGUYRKSA-N 0.000 description 1
- RUAJTZOFBHDMLR-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-methyl-6-[(2-methylpropan-2-yl)oxy]hexanoic acid Chemical compound CC(C)(C)OC[C@@H](C)C[C@H](CN)CC(O)=O RUAJTZOFBHDMLR-UWVGGRQHSA-N 0.000 description 1
- GVEBXLCIMGRADW-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-5-methyl-6-[2-(trifluoromethyl)phenoxy]hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)COC1=CC=CC=C1C(F)(F)F GVEBXLCIMGRADW-QWRGUYRKSA-N 0.000 description 1
- AVQINEYZXFUJAE-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-5-methyl-6-[3-(trifluoromethyl)phenoxy]hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)COC1=CC=CC(C(F)(F)F)=C1 AVQINEYZXFUJAE-QWRGUYRKSA-N 0.000 description 1
- GABLMMUZBCSETM-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-5-methyl-6-[4-(trifluoromethyl)phenoxy]hexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)COC1=CC=C(C(F)(F)F)C=C1 GABLMMUZBCSETM-QWRGUYRKSA-N 0.000 description 1
- BJWHSIOTKMHQKJ-RYUDHWBXSA-N (3s,5s)-3-(aminomethyl)-5-methyl-6-phenoxyhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)COC1=CC=CC=C1 BJWHSIOTKMHQKJ-RYUDHWBXSA-N 0.000 description 1
- DRIURBCCQVCUNG-JSGCOSHPSA-N (3s,5s)-3-(aminomethyl)-5-methyl-6-phenylmethoxyhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)COCC1=CC=CC=C1 DRIURBCCQVCUNG-JSGCOSHPSA-N 0.000 description 1
- UFLWTYULDKQWKG-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-methyl-6-propan-2-yloxyhexanoic acid Chemical compound CC(C)OC[C@@H](C)C[C@H](CN)CC(O)=O UFLWTYULDKQWKG-UWVGGRQHSA-N 0.000 description 1
- BEYSDHKTOVCIOB-UWVGGRQHSA-N (3s,5s)-3-(aminomethyl)-5-methyl-6-propoxyhexanoic acid Chemical compound CCCOC[C@@H](C)C[C@H](CN)CC(O)=O BEYSDHKTOVCIOB-UWVGGRQHSA-N 0.000 description 1
- FUMMVDSYJMVECH-NEPJUHHUSA-N (3s,5s)-3-(aminomethyl)-5-methyl-7-(2-nitrophenoxy)heptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCOC1=CC=CC=C1[N+]([O-])=O FUMMVDSYJMVECH-NEPJUHHUSA-N 0.000 description 1
- SNQMAXBEHFPZCZ-ZJUUUORDSA-N (3s,5s)-3-(aminomethyl)-5-methyl-7-(3,3,3-trifluoropropoxy)heptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCOCCC(F)(F)F SNQMAXBEHFPZCZ-ZJUUUORDSA-N 0.000 description 1
- VNKAMKYRDSCVMP-NEPJUHHUSA-N (3s,5s)-3-(aminomethyl)-5-methyl-7-(3-nitrophenoxy)heptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCOC1=CC=CC([N+]([O-])=O)=C1 VNKAMKYRDSCVMP-NEPJUHHUSA-N 0.000 description 1
- ZTSGAKHFFATMAK-NEPJUHHUSA-N (3s,5s)-3-(aminomethyl)-5-methyl-7-(4-nitrophenoxy)heptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCOC1=CC=C([N+]([O-])=O)C=C1 ZTSGAKHFFATMAK-NEPJUHHUSA-N 0.000 description 1
- VBNZQEATURTZIC-MNOVXSKESA-N (3s,5s)-3-(aminomethyl)-5-methyl-7-[(2-methylpropan-2-yl)oxy]heptanoic acid Chemical compound CC(C)(C)OCC[C@@H](C)C[C@H](CN)CC(O)=O VBNZQEATURTZIC-MNOVXSKESA-N 0.000 description 1
- SHVBXBWRDPXTKX-NEPJUHHUSA-N (3s,5s)-3-(aminomethyl)-5-methyl-7-[2-(trifluoromethyl)phenoxy]heptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCOC1=CC=CC=C1C(F)(F)F SHVBXBWRDPXTKX-NEPJUHHUSA-N 0.000 description 1
- OFGWHKIYXBXOJA-NEPJUHHUSA-N (3s,5s)-3-(aminomethyl)-5-methyl-7-[3-(trifluoromethyl)phenoxy]heptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCOC1=CC=CC(C(F)(F)F)=C1 OFGWHKIYXBXOJA-NEPJUHHUSA-N 0.000 description 1
- OCUYTLPGBDGFJX-NEPJUHHUSA-N (3s,5s)-3-(aminomethyl)-5-methyl-7-[4-(trifluoromethyl)phenoxy]heptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCOC1=CC=C(C(F)(F)F)C=C1 OCUYTLPGBDGFJX-NEPJUHHUSA-N 0.000 description 1
- UFZIRWJCIMWPCS-OLZOCXBDSA-N (3s,5s)-3-(aminomethyl)-5-methyl-7-phenoxyheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCOC1=CC=CC=C1 UFZIRWJCIMWPCS-OLZOCXBDSA-N 0.000 description 1
- CZDWSLQQEXYPEZ-HIFRSBDPSA-N (3s,5s)-3-(aminomethyl)-5-methyl-7-phenylmethoxyheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCOCC1=CC=CC=C1 CZDWSLQQEXYPEZ-HIFRSBDPSA-N 0.000 description 1
- JFSPWJQYNAIJDM-MNOVXSKESA-N (3s,5s)-3-(aminomethyl)-5-methyl-7-propan-2-yloxyheptanoic acid Chemical compound CC(C)OCC[C@@H](C)C[C@H](CN)CC(O)=O JFSPWJQYNAIJDM-MNOVXSKESA-N 0.000 description 1
- SQOWNMIWVUTXJT-MNOVXSKESA-N (3s,5s)-3-(aminomethyl)-5-methyl-7-propoxyheptanoic acid Chemical compound CCCOCC[C@@H](C)C[C@H](CN)CC(O)=O SQOWNMIWVUTXJT-MNOVXSKESA-N 0.000 description 1
- IDWNAISYDJCEER-SFYZADRCSA-N (3s,5s)-3-(aminomethyl)-5-methylhept-6-enoic acid Chemical compound C=C[C@@H](C)C[C@H](CN)CC(O)=O IDWNAISYDJCEER-SFYZADRCSA-N 0.000 description 1
- MYAOGFDZMOXKAG-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-5-phenoxyhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)OC1=CC=CC=C1 MYAOGFDZMOXKAG-QWRGUYRKSA-N 0.000 description 1
- HBKQWQFIUGDJOB-IUCAKERBSA-N (3s,5s)-3-(aminomethyl)-5-propan-2-yloxyhexanoic acid Chemical compound CC(C)O[C@@H](C)C[C@H](CN)CC(O)=O HBKQWQFIUGDJOB-IUCAKERBSA-N 0.000 description 1
- AMBOZTYDXCXROW-IUCAKERBSA-N (3s,5s)-3-(aminomethyl)-5-propoxyhexanoic acid Chemical compound CCCO[C@@H](C)C[C@H](CN)CC(O)=O AMBOZTYDXCXROW-IUCAKERBSA-N 0.000 description 1
- YEAUVJOYGXJVPQ-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-6-(2-chlorophenoxy)-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)COC1=CC=CC=C1Cl YEAUVJOYGXJVPQ-QWRGUYRKSA-N 0.000 description 1
- ZVAKZSCJKNCURF-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-6-(2-chlorophenyl)-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CC1=CC=CC=C1Cl ZVAKZSCJKNCURF-QWRGUYRKSA-N 0.000 description 1
- XKHPYADDLBOYCB-IUCAKERBSA-N (3s,5s)-3-(aminomethyl)-6-(2-fluoroethoxy)-5-methylhexanoic acid Chemical compound FCCOC[C@@H](C)C[C@H](CN)CC(O)=O XKHPYADDLBOYCB-IUCAKERBSA-N 0.000 description 1
- ILLWSZLMKZNZPN-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-6-(2-fluorophenoxy)-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)COC1=CC=CC=C1F ILLWSZLMKZNZPN-QWRGUYRKSA-N 0.000 description 1
- BDBBMYYIQJOZRO-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-6-(2-fluorophenyl)-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CC1=CC=CC=C1F BDBBMYYIQJOZRO-QWRGUYRKSA-N 0.000 description 1
- PTLPNAYVPVGVNV-RYUDHWBXSA-N (3s,5s)-3-(aminomethyl)-6-(2-methoxyphenoxy)-5-methylhexanoic acid Chemical compound COC1=CC=CC=C1OC[C@@H](C)C[C@H](CN)CC(O)=O PTLPNAYVPVGVNV-RYUDHWBXSA-N 0.000 description 1
- RXUNPZIYFFDPIM-RYUDHWBXSA-N (3s,5s)-3-(aminomethyl)-6-(2-methoxyphenyl)-5-methylhexanoic acid Chemical compound COC1=CC=CC=C1C[C@@H](C)C[C@H](CN)CC(O)=O RXUNPZIYFFDPIM-RYUDHWBXSA-N 0.000 description 1
- SYEGAVIXXAKPJU-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-6-(3-chlorophenoxy)-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)COC1=CC=CC(Cl)=C1 SYEGAVIXXAKPJU-QWRGUYRKSA-N 0.000 description 1
- NHLRGBJJTDTMMO-PWSUYJOCSA-N (3s,5s)-3-(aminomethyl)-6-(3-chlorophenyl)-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CC1=CC=CC(Cl)=C1 NHLRGBJJTDTMMO-PWSUYJOCSA-N 0.000 description 1
- HLGINTCDPKNHLH-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-6-(3-fluorophenoxy)-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)COC1=CC=CC(F)=C1 HLGINTCDPKNHLH-QWRGUYRKSA-N 0.000 description 1
- IWJOISGPGPHPDW-PWSUYJOCSA-N (3s,5s)-3-(aminomethyl)-6-(3-fluorophenyl)-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CC1=CC=CC(F)=C1 IWJOISGPGPHPDW-PWSUYJOCSA-N 0.000 description 1
- QNLPCHJCQBHOFT-RYUDHWBXSA-N (3s,5s)-3-(aminomethyl)-6-(3-methoxyphenoxy)-5-methylhexanoic acid Chemical compound COC1=CC=CC(OC[C@@H](C)C[C@H](CN)CC(O)=O)=C1 QNLPCHJCQBHOFT-RYUDHWBXSA-N 0.000 description 1
- REMVOPFUXXGFNX-YPMHNXCESA-N (3s,5s)-3-(aminomethyl)-6-(3-methoxyphenyl)-5-methylhexanoic acid Chemical compound COC1=CC=CC(C[C@@H](C)C[C@H](CN)CC(O)=O)=C1 REMVOPFUXXGFNX-YPMHNXCESA-N 0.000 description 1
- BTDDWLPKAPLZPD-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-6-(4-chlorophenoxy)-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)COC1=CC=C(Cl)C=C1 BTDDWLPKAPLZPD-QWRGUYRKSA-N 0.000 description 1
- LSACENQGZOTOGG-PWSUYJOCSA-N (3s,5s)-3-(aminomethyl)-6-(4-chlorophenyl)-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CC1=CC=C(Cl)C=C1 LSACENQGZOTOGG-PWSUYJOCSA-N 0.000 description 1
- OESSABKVIANOLH-QWRGUYRKSA-N (3s,5s)-3-(aminomethyl)-6-(4-fluorophenoxy)-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)COC1=CC=C(F)C=C1 OESSABKVIANOLH-QWRGUYRKSA-N 0.000 description 1
- BNSXDZMADNOZMO-PWSUYJOCSA-N (3s,5s)-3-(aminomethyl)-6-(4-fluorophenyl)-5-methylhexanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CC1=CC=C(F)C=C1 BNSXDZMADNOZMO-PWSUYJOCSA-N 0.000 description 1
- PQJCGTNFSFNAGC-YPMHNXCESA-N (3s,5s)-3-(aminomethyl)-6-(4-methoxyphenyl)-5-methylhexanoic acid Chemical compound COC1=CC=C(C[C@@H](C)C[C@H](CN)CC(O)=O)C=C1 PQJCGTNFSFNAGC-YPMHNXCESA-N 0.000 description 1
- OLNFZYBQOUBMKG-YUMQZZPRSA-N (3s,5s)-3-(aminomethyl)-6-(fluoromethoxy)-5-methylhexanoic acid Chemical compound FCOC[C@@H](C)C[C@H](CN)CC(O)=O OLNFZYBQOUBMKG-YUMQZZPRSA-N 0.000 description 1
- MLTLRMPTBXSGIZ-IUCAKERBSA-N (3s,5s)-3-(aminomethyl)-6-ethoxy-5-methylhexanoic acid Chemical compound CCOC[C@@H](C)C[C@H](CN)CC(O)=O MLTLRMPTBXSGIZ-IUCAKERBSA-N 0.000 description 1
- FLXDBXNBVCOMNM-BQBZGAKWSA-N (3s,5s)-3-(aminomethyl)-6-fluoro-5-methylhexanoic acid Chemical compound FC[C@@H](C)C[C@H](CN)CC(O)=O FLXDBXNBVCOMNM-BQBZGAKWSA-N 0.000 description 1
- OJKUJPIRCGOCSG-BQBZGAKWSA-N (3s,5s)-3-(aminomethyl)-6-hydroxy-5-methylhexanoic acid Chemical compound OC[C@@H](C)C[C@H](CN)CC(O)=O OJKUJPIRCGOCSG-BQBZGAKWSA-N 0.000 description 1
- KNHVAHZLVNDEFH-YUMQZZPRSA-N (3s,5s)-3-(aminomethyl)-6-methoxy-5-methylhexanoic acid Chemical compound COC[C@@H](C)C[C@H](CN)CC(O)=O KNHVAHZLVNDEFH-YUMQZZPRSA-N 0.000 description 1
- JAKCHAABXQZLJL-BQBZGAKWSA-N (3s,5s)-3-(aminomethyl)-7,7,7-trifluoro-5-methylheptanoic acid Chemical compound FC(F)(F)C[C@@H](C)C[C@H](CN)CC(O)=O JAKCHAABXQZLJL-BQBZGAKWSA-N 0.000 description 1
- UXADRPDGLMXORZ-NEPJUHHUSA-N (3s,5s)-3-(aminomethyl)-7-(2-chlorophenoxy)-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCOC1=CC=CC=C1Cl UXADRPDGLMXORZ-NEPJUHHUSA-N 0.000 description 1
- AYQQVGAVUXFTQT-ZJUUUORDSA-N (3s,5s)-3-(aminomethyl)-7-(2-fluoroethoxy)-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCOCCF AYQQVGAVUXFTQT-ZJUUUORDSA-N 0.000 description 1
- WSJXJYHCQWTQQO-NEPJUHHUSA-N (3s,5s)-3-(aminomethyl)-7-(2-fluorophenoxy)-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCOC1=CC=CC=C1F WSJXJYHCQWTQQO-NEPJUHHUSA-N 0.000 description 1
- VQVPILUHTBGANF-OLZOCXBDSA-N (3s,5s)-3-(aminomethyl)-7-(2-methoxyphenoxy)-5-methylheptanoic acid Chemical compound COC1=CC=CC=C1OCC[C@@H](C)C[C@H](CN)CC(O)=O VQVPILUHTBGANF-OLZOCXBDSA-N 0.000 description 1
- LJXDNFZTTZQSKO-NEPJUHHUSA-N (3s,5s)-3-(aminomethyl)-7-(3-chlorophenoxy)-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCOC1=CC=CC(Cl)=C1 LJXDNFZTTZQSKO-NEPJUHHUSA-N 0.000 description 1
- JHKPYIKSXQNDJF-NEPJUHHUSA-N (3s,5s)-3-(aminomethyl)-7-(3-fluorophenoxy)-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCOC1=CC=CC(F)=C1 JHKPYIKSXQNDJF-NEPJUHHUSA-N 0.000 description 1
- MSXHKKCCRAYPPX-OLZOCXBDSA-N (3s,5s)-3-(aminomethyl)-7-(3-methoxyphenoxy)-5-methylheptanoic acid Chemical compound COC1=CC=CC(OCC[C@@H](C)C[C@H](CN)CC(O)=O)=C1 MSXHKKCCRAYPPX-OLZOCXBDSA-N 0.000 description 1
- ILGDLVFKEURNOD-NEPJUHHUSA-N (3s,5s)-3-(aminomethyl)-7-(4-chlorophenoxy)-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCOC1=CC=C(Cl)C=C1 ILGDLVFKEURNOD-NEPJUHHUSA-N 0.000 description 1
- YJDWLYFZXSNACU-NEPJUHHUSA-N (3s,5s)-3-(aminomethyl)-7-(4-fluorophenoxy)-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](CN)C[C@H](C)CCOC1=CC=C(F)C=C1 YJDWLYFZXSNACU-NEPJUHHUSA-N 0.000 description 1
- AFFYXOJEDVNKNJ-OLZOCXBDSA-N (3s,5s)-3-(aminomethyl)-7-(4-methoxyphenoxy)-5-methylheptanoic acid Chemical compound COC1=CC=C(OCC[C@@H](C)C[C@H](CN)CC(O)=O)C=C1 AFFYXOJEDVNKNJ-OLZOCXBDSA-N 0.000 description 1
- AKZJPWVUJZKCMJ-BDAKNGLRSA-N (3s,5s)-3-(aminomethyl)-7-(fluoromethoxy)-5-methylheptanoic acid Chemical compound FCOCC[C@@H](C)C[C@H](CN)CC(O)=O AKZJPWVUJZKCMJ-BDAKNGLRSA-N 0.000 description 1
- UKCMEZKOGLCILO-ZJUUUORDSA-N (3s,5s)-3-(aminomethyl)-7-ethoxy-5-methylheptanoic acid Chemical compound CCOCC[C@@H](C)C[C@H](CN)CC(O)=O UKCMEZKOGLCILO-ZJUUUORDSA-N 0.000 description 1
- GEYGHNUUWOVRDW-SFYZADRCSA-N (3s,5s)-3-(aminomethyl)-7-fluoro-5-methylheptanoic acid Chemical compound FCC[C@@H](C)C[C@H](CN)CC(O)=O GEYGHNUUWOVRDW-SFYZADRCSA-N 0.000 description 1
- WGDYBZSHIFLGMT-SFYZADRCSA-N (3s,5s)-3-(aminomethyl)-7-hydroxy-5-methylheptanoic acid Chemical compound OCC[C@@H](C)C[C@H](CN)CC(O)=O WGDYBZSHIFLGMT-SFYZADRCSA-N 0.000 description 1
- GZZGIZGZNKGONB-BDAKNGLRSA-N (3s,5s)-3-(aminomethyl)-7-methoxy-5-methylheptanoic acid Chemical compound COCC[C@@H](C)C[C@H](CN)CC(O)=O GZZGIZGZNKGONB-BDAKNGLRSA-N 0.000 description 1
- KOWIZHDULJSRPT-WUKNDPDISA-N (3z)-3-[(4-bromophenyl)-(4-methylsulfonylphenyl)methylidene]oxolan-2-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(\C=1C=CC(Br)=CC=1)=C/1C(=O)OCC\1 KOWIZHDULJSRPT-WUKNDPDISA-N 0.000 description 1
- VVQCRZGVHVDBMB-OKWQPMOJSA-N (e,3s,5r)-3-(aminomethyl)-5-methylnon-7-enoic acid Chemical compound C\C=C\C[C@@H](C)C[C@H](CN)CC(O)=O VVQCRZGVHVDBMB-OKWQPMOJSA-N 0.000 description 1
- YQAUPMUIFNJUOC-AIIUZBJTSA-N (e,3s,5r)-3-(aminomethyl)-5-methylundec-7-enoic acid Chemical compound CCC\C=C\C[C@@H](C)C[C@H](CN)CC(O)=O YQAUPMUIFNJUOC-AIIUZBJTSA-N 0.000 description 1
- ZMUPGDMHVPLGIG-CFUOYWMPSA-N (e,3s,5s)-3-(aminomethyl)-5-methylnon-6-enoic acid Chemical compound CC\C=C\[C@@H](C)C[C@H](CN)CC(O)=O ZMUPGDMHVPLGIG-CFUOYWMPSA-N 0.000 description 1
- HEHWAGOHHVUWGC-BKIAHZASSA-N (e,3s,5s)-3-(aminomethyl)-5-methyloct-6-enoic acid Chemical compound C\C=C\[C@@H](C)C[C@H](CN)CC(O)=O HEHWAGOHHVUWGC-BKIAHZASSA-N 0.000 description 1
- INGBDMMBKJIDFL-KWKBKKAHSA-N (z,3s,5r)-3-(aminomethyl)-5-methyldec-7-enoic acid Chemical compound CC\C=C/C[C@@H](C)C[C@H](CN)CC(O)=O INGBDMMBKJIDFL-KWKBKKAHSA-N 0.000 description 1
- VVQCRZGVHVDBMB-QKMQQOOLSA-N (z,3s,5r)-3-(aminomethyl)-5-methylnon-7-enoic acid Chemical compound C\C=C/C[C@@H](C)C[C@H](CN)CC(O)=O VVQCRZGVHVDBMB-QKMQQOOLSA-N 0.000 description 1
- ZMUPGDMHVPLGIG-OOMSKYPHSA-N (z,3s,5s)-3-(aminomethyl)-5-methylnon-6-enoic acid Chemical compound CC\C=C/[C@@H](C)C[C@H](CN)CC(O)=O ZMUPGDMHVPLGIG-OOMSKYPHSA-N 0.000 description 1
- HEHWAGOHHVUWGC-NESOUNQCSA-N (z,3s,5s)-3-(aminomethyl)-5-methyloct-6-enoic acid Chemical compound C\C=C/[C@@H](C)C[C@H](CN)CC(O)=O HEHWAGOHHVUWGC-NESOUNQCSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- HFWZBWTWCKQUCB-RVDMUPIBSA-N 2,6-ditert-butyl-4-[(e)-(2-ethyl-1,1-dioxo-1,2-thiazolidin-5-ylidene)methyl]phenol Chemical compound O=S1(=O)N(CC)CC\C1=C/C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 HFWZBWTWCKQUCB-RVDMUPIBSA-N 0.000 description 1
- JEVOLBNIBQRSJX-UHFFFAOYSA-N 2-(2,5-dihydro-1,2,4-oxadiazol-3-ylmethyl)-4-methylpentan-1-amine Chemical compound CC(C)CC(CN)CC1=NCON1 JEVOLBNIBQRSJX-UHFFFAOYSA-N 0.000 description 1
- XNTLXAUHLBBEKP-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-(4-methylsulfonylphenyl)pyridazin-3-one Chemical compound O=C1C(OCCC(C)(O)C)=C(C=2C=CC(=CC=2)S(C)(=O)=O)C=NN1C1=CC=C(F)C(F)=C1 XNTLXAUHLBBEKP-UHFFFAOYSA-N 0.000 description 1
- OPAXRDNEIABTQI-VIFPVBQESA-N 2-[(1r)-1-(aminomethyl)-2,2-dimethylcyclobutyl]acetic acid Chemical compound CC1(C)CC[C@@]1(CN)CC(O)=O OPAXRDNEIABTQI-VIFPVBQESA-N 0.000 description 1
- DNHPJOLWCOXHOV-JTQLQIEISA-N 2-[(1r)-1-(aminomethyl)-2,2-dimethylcyclopentyl]acetic acid Chemical compound CC1(C)CCC[C@@]1(CN)CC(O)=O DNHPJOLWCOXHOV-JTQLQIEISA-N 0.000 description 1
- SIKUEILNNOXUAZ-LBPRGKRZSA-N 2-[(1r)-1-(aminomethyl)-3,3-diethylcyclopentyl]acetic acid Chemical compound CCC1(CC)CC[C@](CN)(CC(O)=O)C1 SIKUEILNNOXUAZ-LBPRGKRZSA-N 0.000 description 1
- ZONTWIUNHYLDLZ-JTQLQIEISA-N 2-[(1r)-1-(aminomethyl)-3,3-dimethylcyclopentyl]-n-hydroxyacetamide Chemical compound CC1(C)CC[C@](CN)(CC(=O)NO)C1 ZONTWIUNHYLDLZ-JTQLQIEISA-N 0.000 description 1
- QZBKCCCUSMQVTC-JTQLQIEISA-N 2-[(1r)-1-(aminomethyl)-3,3-dimethylcyclopentyl]acetic acid Chemical compound CC1(C)CC[C@](CN)(CC(O)=O)C1 QZBKCCCUSMQVTC-JTQLQIEISA-N 0.000 description 1
- OPAXRDNEIABTQI-SECBINFHSA-N 2-[(1s)-1-(aminomethyl)-2,2-dimethylcyclobutyl]acetic acid Chemical compound CC1(C)CC[C@]1(CN)CC(O)=O OPAXRDNEIABTQI-SECBINFHSA-N 0.000 description 1
- DNHPJOLWCOXHOV-SNVBAGLBSA-N 2-[(1s)-1-(aminomethyl)-2,2-dimethylcyclopentyl]acetic acid Chemical compound CC1(C)CCC[C@]1(CN)CC(O)=O DNHPJOLWCOXHOV-SNVBAGLBSA-N 0.000 description 1
- SIKUEILNNOXUAZ-GFCCVEGCSA-N 2-[(1s)-1-(aminomethyl)-3,3-diethylcyclopentyl]acetic acid Chemical compound CCC1(CC)CC[C@@](CN)(CC(O)=O)C1 SIKUEILNNOXUAZ-GFCCVEGCSA-N 0.000 description 1
- ZONTWIUNHYLDLZ-SNVBAGLBSA-N 2-[(1s)-1-(aminomethyl)-3,3-dimethylcyclopentyl]-n-hydroxyacetamide Chemical compound CC1(C)CC[C@@](CN)(CC(=O)NO)C1 ZONTWIUNHYLDLZ-SNVBAGLBSA-N 0.000 description 1
- QZBKCCCUSMQVTC-SNVBAGLBSA-N 2-[(1s)-1-(aminomethyl)-3,3-dimethylcyclopentyl]acetic acid Chemical compound CC1(C)CC[C@@](CN)(CC(O)=O)C1 QZBKCCCUSMQVTC-SNVBAGLBSA-N 0.000 description 1
- VVJFYFLGWOCDQD-HTQZYQBOSA-N 2-[(2r,5r)-1-(aminomethyl)-2,5-dimethylcyclopentyl]acetic acid Chemical compound C[C@@H]1CC[C@@H](C)C1(CN)CC(O)=O VVJFYFLGWOCDQD-HTQZYQBOSA-N 0.000 description 1
- VVJFYFLGWOCDQD-YUMQZZPRSA-N 2-[(2s,5s)-1-(aminomethyl)-2,5-dimethylcyclopentyl]acetic acid Chemical compound C[C@H]1CC[C@H](C)C1(CN)CC(O)=O VVJFYFLGWOCDQD-YUMQZZPRSA-N 0.000 description 1
- FKLQZOOZJOUECB-VXGBXAGGSA-N 2-[(3r,4r)-1-(aminomethyl)-3,4-di(propan-2-yl)cyclopentyl]acetic acid Chemical compound CC(C)[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C(C)C FKLQZOOZJOUECB-VXGBXAGGSA-N 0.000 description 1
- HBFZWKRCDVWGSA-WOJBJXKFSA-N 2-[(3r,4r)-1-(aminomethyl)-3,4-dibenzylcyclopentyl]acetic acid Chemical compound C([C@@H]1CC(C[C@H]1CC=1C=CC=CC=1)(CC(O)=O)CN)C1=CC=CC=C1 HBFZWKRCDVWGSA-WOJBJXKFSA-N 0.000 description 1
- KOPGUPUTANQKJY-NXEZZACHSA-N 2-[(3r,4r)-1-(aminomethyl)-3,4-diethylcyclopentyl]acetic acid Chemical compound CC[C@@H]1CC(CN)(CC(O)=O)C[C@H]1CC KOPGUPUTANQKJY-NXEZZACHSA-N 0.000 description 1
- BQOLBIIAWFGWEW-HTQZYQBOSA-N 2-[(3r,4r)-1-(aminomethyl)-3,4-dimethylcyclopentyl]-n-hydroxyacetamide Chemical compound C[C@@H]1CC(CN)(CC(=O)NO)C[C@H]1C BQOLBIIAWFGWEW-HTQZYQBOSA-N 0.000 description 1
- IUVMAUQEZFTTFB-HTQZYQBOSA-N 2-[(3r,4r)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid Chemical compound C[C@@H]1CC(CN)(CC(O)=O)C[C@H]1C IUVMAUQEZFTTFB-HTQZYQBOSA-N 0.000 description 1
- BHQDRZBQUNHTBG-ROUUACIJSA-N 2-[(3r,4r)-1-(aminomethyl)-3,4-diphenylcyclopentyl]acetic acid Chemical compound C1([C@H]2[C@@H](CC(C2)(CC(O)=O)CN)C=2C=CC=CC=2)=CC=CC=C1 BHQDRZBQUNHTBG-ROUUACIJSA-N 0.000 description 1
- DPSPUVHOQGLSSE-VXGBXAGGSA-N 2-[(3r,4r)-1-(aminomethyl)-3,4-ditert-butylcyclopentyl]acetic acid Chemical compound CC(C)(C)[C@@H]1CC(CN)(CC(O)=O)C[C@H]1C(C)(C)C DPSPUVHOQGLSSE-VXGBXAGGSA-N 0.000 description 1
- FKLQZOOZJOUECB-RYUDHWBXSA-N 2-[(3s,4s)-1-(aminomethyl)-3,4-di(propan-2-yl)cyclopentyl]acetic acid Chemical compound CC(C)[C@@H]1CC(CN)(CC(O)=O)C[C@H]1C(C)C FKLQZOOZJOUECB-RYUDHWBXSA-N 0.000 description 1
- HBFZWKRCDVWGSA-PMACEKPBSA-N 2-[(3s,4s)-1-(aminomethyl)-3,4-dibenzylcyclopentyl]acetic acid Chemical compound C([C@H]1CC(C[C@@H]1CC=1C=CC=CC=1)(CC(O)=O)CN)C1=CC=CC=C1 HBFZWKRCDVWGSA-PMACEKPBSA-N 0.000 description 1
- BHQDRZBQUNHTBG-QZTJIDSGSA-N 2-[(3s,4s)-1-(aminomethyl)-3,4-diphenylcyclopentyl]acetic acid Chemical compound C1([C@@H]2[C@H](CC(C2)(CC(O)=O)CN)C=2C=CC=CC=2)=CC=CC=C1 BHQDRZBQUNHTBG-QZTJIDSGSA-N 0.000 description 1
- DPSPUVHOQGLSSE-RYUDHWBXSA-N 2-[(3s,4s)-1-(aminomethyl)-3,4-ditert-butylcyclopentyl]acetic acid Chemical compound CC(C)(C)[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C(C)(C)C DPSPUVHOQGLSSE-RYUDHWBXSA-N 0.000 description 1
- XRAYXEBZNYLCBY-UHFFFAOYSA-N 2-[1-(aminomethyl)-2,2,4,4-tetramethylcyclobutyl]acetic acid Chemical compound CC1(C)CC(C)(C)C1(CN)CC(O)=O XRAYXEBZNYLCBY-UHFFFAOYSA-N 0.000 description 1
- PSOWEDFUUXXEHX-UHFFFAOYSA-N 2-[1-(aminomethyl)-2,2,5,5-tetramethylcyclopentyl]acetic acid Chemical compound CC1(C)CCC(C)(C)C1(CN)CC(O)=O PSOWEDFUUXXEHX-UHFFFAOYSA-N 0.000 description 1
- SEPPWOWOFXDAAP-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3,4,4-tetraethylcyclopentyl]acetic acid Chemical compound CCC1(CC)CC(CN)(CC(O)=O)CC1(CC)CC SEPPWOWOFXDAAP-UHFFFAOYSA-N 0.000 description 1
- FLNCTXNXKXKYGH-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3,4,4-tetramethylcyclopentyl]acetic acid Chemical compound CC1(C)CC(CN)(CC(O)=O)CC1(C)C FLNCTXNXKXKYGH-UHFFFAOYSA-N 0.000 description 1
- UWYKQWDIAKQCEJ-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-di(propan-2-yl)cyclobutyl]acetic acid Chemical compound CC(C)C1(C(C)C)CC(CN)(CC(O)=O)C1 UWYKQWDIAKQCEJ-UHFFFAOYSA-N 0.000 description 1
- SRLZVTNHASZZSM-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-dibenzylcyclobutyl]acetic acid Chemical compound C1C(CN)(CC(O)=O)CC1(CC=1C=CC=CC=1)CC1=CC=CC=C1 SRLZVTNHASZZSM-UHFFFAOYSA-N 0.000 description 1
- BSRBEUFYGVVBLO-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-diethylcyclobutyl]acetic acid Chemical compound CCC1(CC)CC(CN)(CC(O)=O)C1 BSRBEUFYGVVBLO-UHFFFAOYSA-N 0.000 description 1
- RVJMNFWHJKSARF-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-dimethylcyclobutyl]-n-hydroxyacetamide Chemical compound CC1(C)CC(CN)(CC(=O)NO)C1 RVJMNFWHJKSARF-UHFFFAOYSA-N 0.000 description 1
- XEXRZUKGFDRWLE-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-dimethylcyclobutyl]acetic acid Chemical compound CC1(C)CC(CN)(CC(O)=O)C1 XEXRZUKGFDRWLE-UHFFFAOYSA-N 0.000 description 1
- FUDBUFIPBPLPHY-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-diphenylcyclobutyl]acetic acid Chemical compound C1C(CN)(CC(O)=O)CC1(C=1C=CC=CC=1)C1=CC=CC=C1 FUDBUFIPBPLPHY-UHFFFAOYSA-N 0.000 description 1
- CYOHDPOYWOPSRK-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,3-ditert-butylcyclobutyl]acetic acid Chemical compound CC(C)(C)C1(C(C)(C)C)CC(CN)(CC(O)=O)C1 CYOHDPOYWOPSRK-UHFFFAOYSA-N 0.000 description 1
- ACDSLMYLIJQFST-UHFFFAOYSA-N 2-[1-(aminomethyl)-3-methylcyclohexyl]-n-hydroxyacetamide Chemical compound CC1CCCC(CN)(CC(=O)NO)C1 ACDSLMYLIJQFST-UHFFFAOYSA-N 0.000 description 1
- UOPIILYKLVDKTK-UHFFFAOYSA-N 2-[1-(aminomethyl)-3-methylcyclohexyl]acetic acid Chemical compound CC1CCCC(CN)(CC(O)=O)C1 UOPIILYKLVDKTK-UHFFFAOYSA-N 0.000 description 1
- HYVKVSAZCPKHDV-UHFFFAOYSA-N 2-[1-(aminomethyl)-3-methylcyclopentyl]acetic acid Chemical compound CC1CCC(CN)(CC(O)=O)C1 HYVKVSAZCPKHDV-UHFFFAOYSA-N 0.000 description 1
- SDJDLWRYIIIDMH-UHFFFAOYSA-N 2-[1-(aminomethyl)cycloheptyl]-n-hydroxyacetamide Chemical compound ONC(=O)CC1(CN)CCCCCC1 SDJDLWRYIIIDMH-UHFFFAOYSA-N 0.000 description 1
- HKBYROVPIYTBLO-UHFFFAOYSA-N 2-[1-(aminomethyl)cyclohexyl]-n-hydroxyacetamide Chemical compound ONC(=O)CC1(CN)CCCCC1 HKBYROVPIYTBLO-UHFFFAOYSA-N 0.000 description 1
- QBFBJAUOZMZGQM-UHFFFAOYSA-N 2-[1-(aminomethyl)cyclopentyl]-n-hydroxyacetamide Chemical compound ONC(=O)CC1(CN)CCCC1 QBFBJAUOZMZGQM-UHFFFAOYSA-N 0.000 description 1
- GQLYDXGALKBIST-UHFFFAOYSA-N 2-[2-(aminomethyl)-2-adamantyl]-n-hydroxyacetamide Chemical compound C1C(C2)CC3CC1C(CN)(CC(=O)NO)C2C3 GQLYDXGALKBIST-UHFFFAOYSA-N 0.000 description 1
- YADLKXGEJRTLBR-UHFFFAOYSA-N 2-[9-(aminomethyl)-9-bicyclo[3.3.1]nonanyl]-n-hydroxyacetamide Chemical compound C1CCC2CCCC1C2(CC(=O)NO)CN YADLKXGEJRTLBR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- BWBQMUPZKXFEIP-UHFFFAOYSA-N 3-(1-aminoethyl)-5-methylheptanoic acid Chemical compound CCC(C)CC(C(C)N)CC(O)=O BWBQMUPZKXFEIP-UHFFFAOYSA-N 0.000 description 1
- IRQCKMBXGOKUDW-UHFFFAOYSA-N 3-(1-azaniumylethyl)-5-methylhexanoate Chemical compound CC(C)CC(C(C)N)CC(O)=O IRQCKMBXGOKUDW-UHFFFAOYSA-N 0.000 description 1
- OUYPRNJUXRLDLW-UHFFFAOYSA-N 3-(3-amino-2-cyclobutylpropyl)-2h-1,2,4-thiadiazol-5-one Chemical compound C1CCC1C(CN)CC1=NSC(=O)N1 OUYPRNJUXRLDLW-UHFFFAOYSA-N 0.000 description 1
- XRTLNMMGRKQIQZ-UHFFFAOYSA-N 3-(3-amino-2-cyclopentylpropyl)-2h-1,2,4-thiadiazol-5-one Chemical compound C1CCCC1C(CN)CC1=NSC(=O)N1 XRTLNMMGRKQIQZ-UHFFFAOYSA-N 0.000 description 1
- KDCBMCJRMVNJSC-UHFFFAOYSA-N 3-(aminomethyl)-4-ethyl-5-methylhexanoic acid Chemical compound CCC(C(C)C)C(CN)CC(O)=O KDCBMCJRMVNJSC-UHFFFAOYSA-N 0.000 description 1
- WQOCZIJPIVWQEL-UHFFFAOYSA-N 3-(aminomethyl)-4-propan-2-yldecanoic acid Chemical compound CCCCCCC(C(C)C)C(CN)CC(O)=O WQOCZIJPIVWQEL-UHFFFAOYSA-N 0.000 description 1
- MANPXHGDIYSTEN-UHFFFAOYSA-N 3-(aminomethyl)-4-propan-2-ylheptanoic acid Chemical compound CCCC(C(C)C)C(CN)CC(O)=O MANPXHGDIYSTEN-UHFFFAOYSA-N 0.000 description 1
- XLNITVUBTMJFSS-UHFFFAOYSA-N 3-(aminomethyl)-4-propan-2-ylnonanoic acid Chemical compound CCCCCC(C(C)C)C(CN)CC(O)=O XLNITVUBTMJFSS-UHFFFAOYSA-N 0.000 description 1
- FNKFLSKSEWXIJR-UHFFFAOYSA-N 3-(aminomethyl)-4-propan-2-yloctanoic acid Chemical compound CCCCC(C(C)C)C(CN)CC(O)=O FNKFLSKSEWXIJR-UHFFFAOYSA-N 0.000 description 1
- MZXNUBDMHKYIDC-UHFFFAOYSA-N 3-(aminomethyl)-5-(2-chlorophenyl)hexanoic acid Chemical compound OC(=O)CC(CN)CC(C)C1=CC=CC=C1Cl MZXNUBDMHKYIDC-UHFFFAOYSA-N 0.000 description 1
- AVDPWOUCNFZVNY-UHFFFAOYSA-N 3-(aminomethyl)-5-(2-methoxyphenyl)hexanoic acid Chemical compound COC1=CC=CC=C1C(C)CC(CN)CC(O)=O AVDPWOUCNFZVNY-UHFFFAOYSA-N 0.000 description 1
- YODGVKRANQWMHX-UHFFFAOYSA-N 3-(aminomethyl)-5-(3-chlorophenyl)hexanoic acid Chemical compound OC(=O)CC(CN)CC(C)C1=CC=CC(Cl)=C1 YODGVKRANQWMHX-UHFFFAOYSA-N 0.000 description 1
- WIXDCNGDWLJMRA-UHFFFAOYSA-N 3-(aminomethyl)-5-(3-methoxyphenyl)hexanoic acid Chemical compound COC1=CC=CC(C(C)CC(CN)CC(O)=O)=C1 WIXDCNGDWLJMRA-UHFFFAOYSA-N 0.000 description 1
- GMEHPYLOPWSWPM-UHFFFAOYSA-N 3-(aminomethyl)-5-(4-chlorophenyl)hexanoic acid Chemical compound OC(=O)CC(CN)CC(C)C1=CC=C(Cl)C=C1 GMEHPYLOPWSWPM-UHFFFAOYSA-N 0.000 description 1
- OILXZDNEKPMMNR-UHFFFAOYSA-N 3-(aminomethyl)-5-(4-methoxyphenyl)hexanoic acid Chemical compound COC1=CC=C(C(C)CC(CN)CC(O)=O)C=C1 OILXZDNEKPMMNR-UHFFFAOYSA-N 0.000 description 1
- NECOLRNJBIIURC-UHFFFAOYSA-N 3-(aminomethyl)-5-cyclobutylhexanoic acid Chemical compound OC(=O)CC(CN)CC(C)C1CCC1 NECOLRNJBIIURC-UHFFFAOYSA-N 0.000 description 1
- QIVMNCBZDTZSSL-UHFFFAOYSA-N 3-(aminomethyl)-5-cyclohexylhexanoic acid Chemical compound OC(=O)CC(CN)CC(C)C1CCCCC1 QIVMNCBZDTZSSL-UHFFFAOYSA-N 0.000 description 1
- SCUJBZYQUHOYMH-UHFFFAOYSA-N 3-(aminomethyl)-5-cyclopentylhexanoic acid Chemical compound OC(=O)CC(CN)CC(C)C1CCCC1 SCUJBZYQUHOYMH-UHFFFAOYSA-N 0.000 description 1
- KPXGGTAOFKPJCB-UHFFFAOYSA-N 3-(aminomethyl)-5-cyclopropylhexanoic acid Chemical compound OC(=O)CC(CN)CC(C)C1CC1 KPXGGTAOFKPJCB-UHFFFAOYSA-N 0.000 description 1
- SZPNHBKBLPROKB-UHFFFAOYSA-N 3-(aminomethyl)-5-methyl-4-phenylhexanoic acid Chemical compound OC(=O)CC(CN)C(C(C)C)C1=CC=CC=C1 SZPNHBKBLPROKB-UHFFFAOYSA-N 0.000 description 1
- JBBFMHZVKGOWPT-UHFFFAOYSA-N 3-(aminomethyl)-5-methyl-6-phenylhexanoic acid Chemical compound OC(=O)CC(CN)CC(C)CC1=CC=CC=C1 JBBFMHZVKGOWPT-UHFFFAOYSA-N 0.000 description 1
- JETOEPZFEWLXBK-UHFFFAOYSA-N 3-(aminomethyl)-5-methyldecanoic acid Chemical compound CCCCCC(C)CC(CN)CC(O)=O JETOEPZFEWLXBK-UHFFFAOYSA-N 0.000 description 1
- IMLWGNYZSUWXIA-UHFFFAOYSA-N 3-(aminomethyl)-5-methyldodecanoic acid Chemical compound CCCCCCCC(C)CC(CN)CC(O)=O IMLWGNYZSUWXIA-UHFFFAOYSA-N 0.000 description 1
- SIRQBZJUYVPMIC-UHFFFAOYSA-N 3-(aminomethyl)-5-methylheptanoic acid Chemical compound CCC(C)CC(CN)CC(O)=O SIRQBZJUYVPMIC-UHFFFAOYSA-N 0.000 description 1
- KUSIIZRBOLFILF-UHFFFAOYSA-N 3-(aminomethyl)-5-methylnonanoic acid Chemical compound CCCCC(C)CC(CN)CC(O)=O KUSIIZRBOLFILF-UHFFFAOYSA-N 0.000 description 1
- KKXFMWXZXDUYBF-UHFFFAOYSA-N 3-(aminomethyl)-5-methyloctanoic acid Chemical compound CCCC(C)CC(CN)CC(O)=O KKXFMWXZXDUYBF-UHFFFAOYSA-N 0.000 description 1
- TZOKXKRKSNVJGE-UHFFFAOYSA-N 3-(aminomethyl)-5-methyltridecanoic acid Chemical compound CCCCCCCCC(C)CC(CN)CC(O)=O TZOKXKRKSNVJGE-UHFFFAOYSA-N 0.000 description 1
- HLRPRVFNTZZSHY-UHFFFAOYSA-N 3-(aminomethyl)-5-methylundecanoic acid Chemical compound CCCCCCC(C)CC(CN)CC(O)=O HLRPRVFNTZZSHY-UHFFFAOYSA-N 0.000 description 1
- ACARJIZTCQNHBW-UHFFFAOYSA-N 3-(aminomethyl)-5-phenylhexanoic acid Chemical compound OC(=O)CC(CN)CC(C)C1=CC=CC=C1 ACARJIZTCQNHBW-UHFFFAOYSA-N 0.000 description 1
- USSUQFWPXUAXPB-UHFFFAOYSA-N 3-(aminomethyl)-6,6,6-trifluoro-5-methylhexanoic acid Chemical compound FC(F)(F)C(C)CC(CN)CC(O)=O USSUQFWPXUAXPB-UHFFFAOYSA-N 0.000 description 1
- WKFQEJHEFGVNGQ-NSHDSACASA-N 3-[[(1r)-1-(aminomethyl)-3,3-dimethylcyclopentyl]methyl]-2h-1,2,4-thiadiazol-5-one Chemical compound C1C(C)(C)CC[C@]1(CN)CC1=NSC(=O)N1 WKFQEJHEFGVNGQ-NSHDSACASA-N 0.000 description 1
- AIWARZDEPWJRDC-LLVKDONJSA-N 3-[[(1s)-1-(aminomethyl)-3,3-dimethylcyclopentyl]methyl]-2h-1,2,4-oxadiazole-5-thione Chemical compound C1C(C)(C)CC[C@@]1(CN)CC1=NOC(=S)N1 AIWARZDEPWJRDC-LLVKDONJSA-N 0.000 description 1
- WKFQEJHEFGVNGQ-LLVKDONJSA-N 3-[[(1s)-1-(aminomethyl)-3,3-dimethylcyclopentyl]methyl]-2h-1,2,4-thiadiazol-5-one Chemical compound C1C(C)(C)CC[C@@]1(CN)CC1=NSC(=O)N1 WKFQEJHEFGVNGQ-LLVKDONJSA-N 0.000 description 1
- RXDXEKHDLCVPDI-HTQZYQBOSA-N 3-[[(3r,4r)-1-(aminomethyl)-3,4-dimethylcyclopentyl]methyl]-2h-1,2,4-oxadiazole-5-thione Chemical compound C1[C@@H](C)[C@H](C)CC1(CN)CC1=NOC(=S)N1 RXDXEKHDLCVPDI-HTQZYQBOSA-N 0.000 description 1
- NICKBMAOPZXAEJ-HTQZYQBOSA-N 3-[[(3r,4r)-1-(aminomethyl)-3,4-dimethylcyclopentyl]methyl]-2h-1,2,4-thiadiazol-5-one Chemical compound C1[C@@H](C)[C@H](C)CC1(CN)CC1=NSC(=O)N1 NICKBMAOPZXAEJ-HTQZYQBOSA-N 0.000 description 1
- FGLLHIYNJXAYPA-UHFFFAOYSA-N 3-[[1-(aminomethyl)-3,3-dimethylcyclobutyl]methyl]-2h-1,2,4-oxadiazole-5-thione Chemical compound C1C(C)(C)CC1(CN)CC1=NOC(=S)N1 FGLLHIYNJXAYPA-UHFFFAOYSA-N 0.000 description 1
- OAYOCOYIUBVRGN-UHFFFAOYSA-N 3-[[1-(aminomethyl)-3,3-dimethylcyclobutyl]methyl]-2h-1,2,4-thiadiazol-5-one Chemical compound C1C(C)(C)CC1(CN)CC1=NSC(=O)N1 OAYOCOYIUBVRGN-UHFFFAOYSA-N 0.000 description 1
- DUXOILFOYWQWLR-UHFFFAOYSA-N 3-[[1-(aminomethyl)-3-methylcyclohexyl]methyl]-2h-1,2,4-oxadiazole-5-thione Chemical compound C1C(C)CCCC1(CN)CC1=NOC(=S)N1 DUXOILFOYWQWLR-UHFFFAOYSA-N 0.000 description 1
- BZXRXGIRWFZDBV-UHFFFAOYSA-N 3-[[1-(aminomethyl)-3-methylcyclohexyl]methyl]-2h-1,2,4-thiadiazol-5-one Chemical compound C1C(C)CCCC1(CN)CC1=NSC(=O)N1 BZXRXGIRWFZDBV-UHFFFAOYSA-N 0.000 description 1
- CYKDJZAVCLPOQA-UHFFFAOYSA-N 3-[[1-(aminomethyl)cycloheptyl]methyl]-2h-1,2,4-oxadiazole-5-thione Chemical compound N=1OC(=S)NC=1CC1(CN)CCCCCC1 CYKDJZAVCLPOQA-UHFFFAOYSA-N 0.000 description 1
- NISSXCGKGSMLOH-UHFFFAOYSA-N 3-[[1-(aminomethyl)cyclohexyl]methyl]-2h-1,2,4-oxadiazole-5-thione Chemical compound N=1OC(=S)NC=1CC1(CN)CCCCC1 NISSXCGKGSMLOH-UHFFFAOYSA-N 0.000 description 1
- TZCVRMGXLBNZEU-UHFFFAOYSA-N 3-[[1-(aminomethyl)cyclohexyl]methyl]-2h-1,2,4-thiadiazol-5-one Chemical compound N=1SC(=O)NC=1CC1(CN)CCCCC1 TZCVRMGXLBNZEU-UHFFFAOYSA-N 0.000 description 1
- PYPDLBWATDGFFS-UHFFFAOYSA-N 3-[[1-(aminomethyl)cyclopentyl]methyl]-2h-1,2,4-oxadiazole-5-thione Chemical compound N=1OC(=S)NC=1CC1(CN)CCCC1 PYPDLBWATDGFFS-UHFFFAOYSA-N 0.000 description 1
- FOWZENRBJKJHBB-UHFFFAOYSA-N 3-[[1-(aminomethyl)cyclopentyl]methyl]-2h-1,2,4-thiadiazol-5-one Chemical compound N=1SC(=O)NC=1CC1(CN)CCCC1 FOWZENRBJKJHBB-UHFFFAOYSA-N 0.000 description 1
- HXBVPQVJCKCUDB-UHFFFAOYSA-N 3-[[2-(aminomethyl)-2-adamantyl]methyl]-2h-1,2,4-oxadiazole-5-thione Chemical compound C1C2CC(C3)CC1CC3C2(CN)CC1=NOC(=S)N1 HXBVPQVJCKCUDB-UHFFFAOYSA-N 0.000 description 1
- BFTYOWLCZHOOPV-UHFFFAOYSA-N 3-[[2-(aminomethyl)-2-adamantyl]methyl]-2h-1,2,4-thiadiazol-5-one Chemical compound C1C2CC(C3)CC1CC3C2(CN)CC1=NSC(=O)N1 BFTYOWLCZHOOPV-UHFFFAOYSA-N 0.000 description 1
- YNCKWQNTFWDZPD-UHFFFAOYSA-N 3-[[9-(aminomethyl)-9-bicyclo[3.3.1]nonanyl]methyl]-2h-1,2,4-oxadiazole-5-thione Chemical compound C1CCC2CCCC1C2(CN)CC1=NOC(=S)N1 YNCKWQNTFWDZPD-UHFFFAOYSA-N 0.000 description 1
- FIHRVPKDARZXJR-UHFFFAOYSA-N 3-[[9-(aminomethyl)-9-bicyclo[3.3.1]nonanyl]methyl]-2h-1,2,4-thiadiazol-5-one Chemical compound C1CCC2CCCC1C2(CN)CC1=NSC(=O)N1 FIHRVPKDARZXJR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- IASDTUBNBCYCJG-UHFFFAOYSA-N 4-methylpregabalin Chemical compound CC(C)C(C)C(CN)CC(O)=O IASDTUBNBCYCJG-UHFFFAOYSA-N 0.000 description 1
- KFGOFTHODYBSGM-IJCBKZNRSA-N 6-Keto-prostaglandin F1a Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC(=O)CCCCC(O)=O KFGOFTHODYBSGM-IJCBKZNRSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- GWVAGCKDTPJGCQ-UHFFFAOYSA-N C/C(/NC(C)=S)=N/O Chemical compound C/C(/NC(C)=S)=N/O GWVAGCKDTPJGCQ-UHFFFAOYSA-N 0.000 description 1
- YAJYEIHCSUSOGP-HQNRFAHOSA-N C1C(C)(C)CC[C@@]1(CN)CC1=NOS(=O)N1 Chemical compound C1C(C)(C)CC[C@@]1(CN)CC1=NOS(=O)N1 YAJYEIHCSUSOGP-HQNRFAHOSA-N 0.000 description 1
- MKHYHJKXHYIWAE-RACNGCFMSA-N C1[C@@H](C)[C@H](C)CC1(CN)CC1=NOS(=O)N1 Chemical compound C1[C@@H](C)[C@H](C)CC1(CN)CC1=NOS(=O)N1 MKHYHJKXHYIWAE-RACNGCFMSA-N 0.000 description 1
- VVCKHHJMPOIXAQ-UHFFFAOYSA-N CC(N1)=NSC1=O Chemical compound CC(N1)=NSC1=O VVCKHHJMPOIXAQ-UHFFFAOYSA-N 0.000 description 1
- YAJYEIHCSUSOGP-VQVVDHBBSA-N CC1(C)CC[C@](CN)(CC2=NOS(=O)N2)C1 Chemical compound CC1(C)CC[C@](CN)(CC2=NOS(=O)N2)C1 YAJYEIHCSUSOGP-VQVVDHBBSA-N 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000283705 Capra hircus Species 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- XZGLNCKSNVGDNX-UHFFFAOYSA-N Cc1nnn[nH]1 Chemical compound Cc1nnn[nH]1 XZGLNCKSNVGDNX-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000033131 Congenital factor II deficiency Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 102000009079 Epoprostenol Receptors Human genes 0.000 description 1
- 108010073099 Epoprostenol Receptors Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 101710129448 Glucose-6-phosphate isomerase 2 Proteins 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000007646 Hypoprothrombinemias Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- BHJVJQCHQOLOSR-UHFFFAOYSA-N N-[2-[1-(aminomethyl)-3-methylcyclohexyl]ethyl]-1,1,1-trifluoromethanesulfonamide Chemical compound CC1CCCC(CN)(CCNS(=O)(=O)C(F)(F)F)C1 BHJVJQCHQOLOSR-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000006538 Nitric Oxide Synthase Type I Human genes 0.000 description 1
- 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 108700023400 Platelet-activating factor receptors Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000034712 Rickettsia Infections Diseases 0.000 description 1
- 206010061495 Rickettsiosis Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XMOREOBNYOKDMM-SECBINFHSA-N [(1r)-1-(aminomethyl)-3,3-dimethylcyclopentyl]methanesulfonamide Chemical compound CC1(C)CC[C@@](CN)(CS(N)(=O)=O)C1 XMOREOBNYOKDMM-SECBINFHSA-N 0.000 description 1
- WPGAQKHDJXNUEM-SECBINFHSA-N [(1r)-1-(aminomethyl)-3,3-dimethylcyclopentyl]methanesulfonic acid Chemical compound CC1(C)CC[C@@](CN)(CS(O)(=O)=O)C1 WPGAQKHDJXNUEM-SECBINFHSA-N 0.000 description 1
- DASRLBOSVBEOQS-SECBINFHSA-N [(1r)-1-(aminomethyl)-3,3-dimethylcyclopentyl]methylphosphonic acid Chemical compound CC1(C)CC[C@@](CN)(CP(O)(O)=O)C1 DASRLBOSVBEOQS-SECBINFHSA-N 0.000 description 1
- AXPYNQKQGUJNSB-JTQLQIEISA-N [(1r)-3,3-dimethyl-1-(2h-tetrazol-5-ylmethyl)cyclopentyl]methanamine Chemical compound C1C(C)(C)CC[C@]1(CN)CC1=NN=NN1 AXPYNQKQGUJNSB-JTQLQIEISA-N 0.000 description 1
- XMOREOBNYOKDMM-VIFPVBQESA-N [(1s)-1-(aminomethyl)-3,3-dimethylcyclopentyl]methanesulfonamide Chemical compound CC1(C)CC[C@](CN)(CS(N)(=O)=O)C1 XMOREOBNYOKDMM-VIFPVBQESA-N 0.000 description 1
- WPGAQKHDJXNUEM-VIFPVBQESA-N [(1s)-1-(aminomethyl)-3,3-dimethylcyclopentyl]methanesulfonic acid Chemical compound CC1(C)CC[C@](CN)(CS(O)(=O)=O)C1 WPGAQKHDJXNUEM-VIFPVBQESA-N 0.000 description 1
- DASRLBOSVBEOQS-VIFPVBQESA-N [(1s)-1-(aminomethyl)-3,3-dimethylcyclopentyl]methylphosphonic acid Chemical compound CC1(C)CC[C@](CN)(CP(O)(O)=O)C1 DASRLBOSVBEOQS-VIFPVBQESA-N 0.000 description 1
- AXPYNQKQGUJNSB-SNVBAGLBSA-N [(1s)-3,3-dimethyl-1-(2h-tetrazol-5-ylmethyl)cyclopentyl]methanamine Chemical compound C1C(C)(C)CC[C@@]1(CN)CC1=NN=NN1 AXPYNQKQGUJNSB-SNVBAGLBSA-N 0.000 description 1
- VWMFPMMAWJKGGU-HTQZYQBOSA-N [(3r,4r)-1-(aminomethyl)-3,4-dimethylcyclopentyl]methanesulfonamide Chemical compound C[C@@H]1CC(CN)(CS(N)(=O)=O)C[C@H]1C VWMFPMMAWJKGGU-HTQZYQBOSA-N 0.000 description 1
- OQVYAGYPTAPIDD-HTQZYQBOSA-N [(3r,4r)-1-(aminomethyl)-3,4-dimethylcyclopentyl]methanesulfonic acid Chemical compound C[C@@H]1CC(CN)(CS(O)(=O)=O)C[C@H]1C OQVYAGYPTAPIDD-HTQZYQBOSA-N 0.000 description 1
- DGYBGGKLAOGVTP-HTQZYQBOSA-N [(3r,4r)-1-(aminomethyl)-3,4-dimethylcyclopentyl]methylphosphonic acid Chemical compound C[C@@H]1CC(CN)(CP(O)(O)=O)C[C@H]1C DGYBGGKLAOGVTP-HTQZYQBOSA-N 0.000 description 1
- YNVVZQUWWLOVIB-HTQZYQBOSA-N [(3r,4r)-3,4-dimethyl-1-(2h-tetrazol-5-ylmethyl)cyclopentyl]methanamine Chemical compound C1[C@@H](C)[C@H](C)CC1(CN)CC1=NN=NN1 YNVVZQUWWLOVIB-HTQZYQBOSA-N 0.000 description 1
- AULKEVUUBZJSRB-UHFFFAOYSA-N [1-(aminomethyl)-3,3-dimethylcyclobutyl]methanesulfonamide Chemical compound CC1(C)CC(CN)(CS(N)(=O)=O)C1 AULKEVUUBZJSRB-UHFFFAOYSA-N 0.000 description 1
- LCPVBYJNZMILGX-UHFFFAOYSA-N [1-(aminomethyl)-3,3-dimethylcyclobutyl]methanesulfonic acid Chemical compound CC1(C)CC(CN)(CS(O)(=O)=O)C1 LCPVBYJNZMILGX-UHFFFAOYSA-N 0.000 description 1
- DDDMKRLWIJLUFH-UHFFFAOYSA-N [1-(aminomethyl)-3,3-dimethylcyclobutyl]methylphosphonic acid Chemical compound CC1(C)CC(CN)(CP(O)(O)=O)C1 DDDMKRLWIJLUFH-UHFFFAOYSA-N 0.000 description 1
- JVTOSAVRBRSNKM-UHFFFAOYSA-N [1-(aminomethyl)-3-methylcyclohexyl]methanesulfonamide Chemical compound CC1CCCC(CN)(CS(N)(=O)=O)C1 JVTOSAVRBRSNKM-UHFFFAOYSA-N 0.000 description 1
- ANTFMGULIQOYJM-UHFFFAOYSA-N [1-(aminomethyl)-3-methylcyclohexyl]methanesulfonic acid Chemical compound CC1CCCC(CN)(CS(O)(=O)=O)C1 ANTFMGULIQOYJM-UHFFFAOYSA-N 0.000 description 1
- RIADRPOWEHYBMG-UHFFFAOYSA-N [1-(aminomethyl)-3-methylcyclohexyl]methylphosphonic acid Chemical compound CC1CCCC(CN)(CP(O)(O)=O)C1 RIADRPOWEHYBMG-UHFFFAOYSA-N 0.000 description 1
- QLZZNFABZXIZCM-UHFFFAOYSA-N [1-(aminomethyl)cycloheptyl]methanesulfonamide Chemical compound NS(=O)(=O)CC1(CN)CCCCCC1 QLZZNFABZXIZCM-UHFFFAOYSA-N 0.000 description 1
- GQXBVVNNHFXNKT-UHFFFAOYSA-N [1-(aminomethyl)cycloheptyl]methanesulfonic acid Chemical compound OS(=O)(=O)CC1(CN)CCCCCC1 GQXBVVNNHFXNKT-UHFFFAOYSA-N 0.000 description 1
- AQFPPALQEDWJFF-UHFFFAOYSA-N [1-(aminomethyl)cycloheptyl]methylphosphonic acid Chemical compound OP(=O)(O)CC1(CN)CCCCCC1 AQFPPALQEDWJFF-UHFFFAOYSA-N 0.000 description 1
- GTSLDHDWPQDRMR-UHFFFAOYSA-N [1-(aminomethyl)cyclohexyl]methanesulfonamide Chemical compound NS(=O)(=O)CC1(CN)CCCCC1 GTSLDHDWPQDRMR-UHFFFAOYSA-N 0.000 description 1
- SRFGZWYLQJNPEF-UHFFFAOYSA-N [1-(aminomethyl)cyclohexyl]methanesulfonic acid Chemical compound OS(=O)(=O)CC1(CN)CCCCC1 SRFGZWYLQJNPEF-UHFFFAOYSA-N 0.000 description 1
- XMTHBBOVDHYRHW-UHFFFAOYSA-N [1-(aminomethyl)cyclopentyl]methanesulfonamide Chemical compound NS(=O)(=O)CC1(CN)CCCC1 XMTHBBOVDHYRHW-UHFFFAOYSA-N 0.000 description 1
- QXRBCXRLASNJRT-UHFFFAOYSA-N [1-(aminomethyl)cyclopentyl]methanesulfonic acid Chemical compound OS(=O)(=O)CC1(CN)CCCC1 QXRBCXRLASNJRT-UHFFFAOYSA-N 0.000 description 1
- OKVZNIWROFVGGM-UHFFFAOYSA-N [1-(aminomethyl)cyclopentyl]methylphosphonic acid Chemical compound OP(=O)(O)CC1(CN)CCCC1 OKVZNIWROFVGGM-UHFFFAOYSA-N 0.000 description 1
- WCYDAKQYHSBBOT-UHFFFAOYSA-N [2-(aminomethyl)-2-adamantyl]methanesulfonamide Chemical compound C1C(C2)CC3CC1C(CN)(CS(N)(=O)=O)C2C3 WCYDAKQYHSBBOT-UHFFFAOYSA-N 0.000 description 1
- WHQBMTRXWPKIFS-UHFFFAOYSA-N [2-(aminomethyl)-2-adamantyl]methanesulfonic acid Chemical compound C1C(C2)CC3CC1C(CN)(CS(O)(=O)=O)C2C3 WHQBMTRXWPKIFS-UHFFFAOYSA-N 0.000 description 1
- FMHIUFXXZAZJKP-UHFFFAOYSA-N [2-(aminomethyl)-2-adamantyl]methylphosphonic acid Chemical compound C1C(C2)CC3CC1C(CN)(CP(O)(O)=O)C2C3 FMHIUFXXZAZJKP-UHFFFAOYSA-N 0.000 description 1
- CJMFUZSVUFPYJR-UHFFFAOYSA-N [2-(aminomethyl)-4-methylpentyl]phosphonic acid Chemical compound CC(C)CC(CN)CP(O)(O)=O CJMFUZSVUFPYJR-UHFFFAOYSA-N 0.000 description 1
- SJWIXWLQZNLVNK-UHFFFAOYSA-N [9-(aminomethyl)-9-bicyclo[3.3.1]nonanyl]methanesulfonamide Chemical compound C1CCC2CCCC1C2(CS(N)(=O)=O)CN SJWIXWLQZNLVNK-UHFFFAOYSA-N 0.000 description 1
- UTBRHDOIPNTSAO-UHFFFAOYSA-N [9-(aminomethyl)-9-bicyclo[3.3.1]nonanyl]methanesulfonic acid Chemical compound C1CCC2CCCC1C2(CS(O)(=O)=O)CN UTBRHDOIPNTSAO-UHFFFAOYSA-N 0.000 description 1
- BEJIEKYFVUJLQX-UHFFFAOYSA-N [9-(aminomethyl)-9-bicyclo[3.3.1]nonanyl]methylphosphonic acid Chemical compound C1CCC2CCCC1C2(CP(O)(O)=O)CN BEJIEKYFVUJLQX-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 206010001053 acute respiratory failure Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 108010003059 aggrecanase Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- VIHAEDVKXSOUAT-UHFFFAOYSA-N but-2-en-4-olide Chemical compound O=C1OCC=C1 VIHAEDVKXSOUAT-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000037410 cognitive enhancement Effects 0.000 description 1
- 238000009226 cognitive therapy Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002792 enkephalinase inhibitor Substances 0.000 description 1
- 238000005837 enolization reaction Methods 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000010228 ex vivo assay Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229940015508 gabapentin 100 mg Drugs 0.000 description 1
- 231100001014 gastrointestinal tract lesion Toxicity 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 201000000284 histiocytoma Diseases 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229940018991 hyalgan Drugs 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
- 229960002367 lasofoxifene Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229940096405 magnesium cation Drugs 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229960001952 metrifonate Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229940101972 mirapex Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- LROIESVTNILZEA-JTQLQIEISA-N n-[2-[(1r)-1-(aminomethyl)-3,3-dimethylcyclopentyl]ethyl]-1,1,1-trifluoromethanesulfonamide Chemical compound CC1(C)CC[C@](CN)(CCNS(=O)(=O)C(F)(F)F)C1 LROIESVTNILZEA-JTQLQIEISA-N 0.000 description 1
- AHDLFZFBRTXUOE-NSHDSACASA-N n-[2-[(1r)-1-(aminomethyl)-3,3-dimethylcyclopentyl]ethyl]methanesulfonamide Chemical compound CC1(C)CC[C@](CN)(CCNS(C)(=O)=O)C1 AHDLFZFBRTXUOE-NSHDSACASA-N 0.000 description 1
- LROIESVTNILZEA-SNVBAGLBSA-N n-[2-[(1s)-1-(aminomethyl)-3,3-dimethylcyclopentyl]ethyl]-1,1,1-trifluoromethanesulfonamide Chemical compound CC1(C)CC[C@@](CN)(CCNS(=O)(=O)C(F)(F)F)C1 LROIESVTNILZEA-SNVBAGLBSA-N 0.000 description 1
- AHDLFZFBRTXUOE-LLVKDONJSA-N n-[2-[(1s)-1-(aminomethyl)-3,3-dimethylcyclopentyl]ethyl]methanesulfonamide Chemical compound CC1(C)CC[C@@](CN)(CCNS(C)(=O)=O)C1 AHDLFZFBRTXUOE-LLVKDONJSA-N 0.000 description 1
- VCCMBMLHCPHYBL-RKDXNWHRSA-N n-[2-[(3r,4r)-1-(aminomethyl)-3,4-dimethylcyclopentyl]ethyl]-1,1,1-trifluoromethanesulfonamide Chemical compound C[C@@H]1CC(CN)(CCNS(=O)(=O)C(F)(F)F)C[C@H]1C VCCMBMLHCPHYBL-RKDXNWHRSA-N 0.000 description 1
- MZLHDSAVPXLKBD-NXEZZACHSA-N n-[2-[(3r,4r)-1-(aminomethyl)-3,4-dimethylcyclopentyl]ethyl]methanesulfonamide Chemical compound C[C@@H]1CC(CN)(CCNS(C)(=O)=O)C[C@H]1C MZLHDSAVPXLKBD-NXEZZACHSA-N 0.000 description 1
- YVKCPEKXFBZJLH-UHFFFAOYSA-N n-[2-[1-(aminomethyl)-3,3-dimethylcyclobutyl]ethyl]-1,1,1-trifluoromethanesulfonamide Chemical compound CC1(C)CC(CN)(CCNS(=O)(=O)C(F)(F)F)C1 YVKCPEKXFBZJLH-UHFFFAOYSA-N 0.000 description 1
- YYJIVWAHSQHIKF-UHFFFAOYSA-N n-[2-[1-(aminomethyl)-3,3-dimethylcyclobutyl]ethyl]methanesulfonamide Chemical compound CC1(C)CC(CN)(CCNS(C)(=O)=O)C1 YYJIVWAHSQHIKF-UHFFFAOYSA-N 0.000 description 1
- ODGINAWRBMEMCV-UHFFFAOYSA-N n-[2-[1-(aminomethyl)-3-methylcyclohexyl]ethyl]methanesulfonamide Chemical compound CC1CCCC(CN)(CCNS(C)(=O)=O)C1 ODGINAWRBMEMCV-UHFFFAOYSA-N 0.000 description 1
- MSNUDYNNVPVGSB-UHFFFAOYSA-N n-[2-[1-(aminomethyl)cycloheptyl]ethyl]-1,1,1-trifluoromethanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NCCC1(CN)CCCCCC1 MSNUDYNNVPVGSB-UHFFFAOYSA-N 0.000 description 1
- JBWVVELZPWDWFW-UHFFFAOYSA-N n-[2-[1-(aminomethyl)cycloheptyl]ethyl]methanesulfonamide Chemical compound CS(=O)(=O)NCCC1(CN)CCCCCC1 JBWVVELZPWDWFW-UHFFFAOYSA-N 0.000 description 1
- DYFUVGALCQUSOZ-UHFFFAOYSA-N n-[2-[1-(aminomethyl)cyclohexyl]ethyl]-1,1,1-trifluoromethanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NCCC1(CN)CCCCC1 DYFUVGALCQUSOZ-UHFFFAOYSA-N 0.000 description 1
- LIXJGZRNWIQRJA-UHFFFAOYSA-N n-[2-[1-(aminomethyl)cyclopentyl]ethyl]-1,1,1-trifluoromethanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NCCC1(CN)CCCC1 LIXJGZRNWIQRJA-UHFFFAOYSA-N 0.000 description 1
- KBPINOMTMTWDSK-UHFFFAOYSA-N n-[2-[1-(aminomethyl)cyclopentyl]ethyl]methanesulfonamide Chemical compound CS(=O)(=O)NCCC1(CN)CCCC1 KBPINOMTMTWDSK-UHFFFAOYSA-N 0.000 description 1
- QXTHUQVXYZTCCJ-UHFFFAOYSA-N n-[2-[2-(aminomethyl)-2-adamantyl]ethyl]-1,1,1-trifluoromethanesulfonamide Chemical compound C1C(C2)CC3CC1C(CN)(CCNS(=O)(=O)C(F)(F)F)C2C3 QXTHUQVXYZTCCJ-UHFFFAOYSA-N 0.000 description 1
- VZDKAUAVCZUTQF-UHFFFAOYSA-N n-[2-[2-(aminomethyl)-2-adamantyl]ethyl]methanesulfonamide Chemical compound C1C(C2)CC3CC1C(CCNS(=O)(=O)C)(CN)C2C3 VZDKAUAVCZUTQF-UHFFFAOYSA-N 0.000 description 1
- JVRAOFNENLWEPP-UHFFFAOYSA-N n-[2-[9-(aminomethyl)-9-bicyclo[3.3.1]nonanyl]ethyl]-1,1,1-trifluoromethanesulfonamide Chemical compound C1CCC2CCCC1C2(CCNS(=O)(=O)C(F)(F)F)CN JVRAOFNENLWEPP-UHFFFAOYSA-N 0.000 description 1
- LHGHLVIXNGYNQZ-UHFFFAOYSA-N n-[2-[9-(aminomethyl)-9-bicyclo[3.3.1]nonanyl]ethyl]methanesulfonamide Chemical compound C1CCC2CCCC1C2(CN)CCNS(=O)(=O)C LHGHLVIXNGYNQZ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229940072228 neurontin Drugs 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 102000030769 platelet activating factor receptor Human genes 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- AYXYPKUFHZROOJ-SSDOTTSWSA-N pregabalin Chemical compound CC(C)C[C@@H](CN)CC(O)=O AYXYPKUFHZROOJ-SSDOTTSWSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 150000003174 prostaglandin I2 derivatives Chemical class 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 201000007183 prothrombin deficiency Diseases 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical compound O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- AGDSCTQQXMDDCV-UHFFFAOYSA-M sodium;2-iodoacetate Chemical compound [Na+].[O-]C(=O)CI AGDSCTQQXMDDCV-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940036220 synvisc Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000009790 vascular invasion Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229940087652 vioxx Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35929502P | 2002-02-22 | 2002-02-22 | |
| US40436502P | 2002-08-19 | 2002-08-19 | |
| PCT/IB2003/000534 WO2003070237A1 (en) | 2002-02-22 | 2003-02-12 | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005523281A true JP2005523281A (ja) | 2005-08-04 |
| JP2005523281A5 JP2005523281A5 (enExample) | 2006-03-30 |
Family
ID=27760521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003569193A Abandoned JP2005523281A (ja) | 2002-02-22 | 2003-02-12 | アルファ−２−デルタリガンドとシクロオキシゲナーゼ−２の選択的阻害剤との組合せ |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20030199567A1 (enExample) |
| EP (1) | EP1480639A1 (enExample) |
| JP (1) | JP2005523281A (enExample) |
| KR (1) | KR20040085216A (enExample) |
| CN (1) | CN1635887A (enExample) |
| AR (1) | AR038531A1 (enExample) |
| AU (1) | AU2003246864A1 (enExample) |
| BR (1) | BR0307906A (enExample) |
| CA (1) | CA2476438A1 (enExample) |
| CO (1) | CO5611109A2 (enExample) |
| HN (1) | HN2003000071A (enExample) |
| IL (1) | IL162932A0 (enExample) |
| MX (1) | MXPA04008175A (enExample) |
| NO (1) | NO20043947L (enExample) |
| PA (1) | PA8567201A1 (enExample) |
| PE (1) | PE20031052A1 (enExample) |
| PL (1) | PL372210A1 (enExample) |
| RU (1) | RU2286151C2 (enExample) |
| TW (1) | TW200303214A (enExample) |
| UY (1) | UY27675A1 (enExample) |
| WO (1) | WO2003070237A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2341240T3 (es) * | 2002-12-13 | 2010-06-17 | Warner-Lambert Company Llc | Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior. |
| JP2006520799A (ja) * | 2003-03-21 | 2006-09-14 | ダイノジェン ファーマシューティカルズ， インコーポレイテッド | 平滑筋調節因子およびα２δサブユニットカルシウムチャネル調節因子を用いた、下部尿路障害を処置するための方法 |
| WO2004084881A1 (en) * | 2003-03-21 | 2004-10-07 | Dynogen Pharmaceuticals, Inc. | METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS |
| WO2004084880A1 (en) * | 2003-03-21 | 2004-10-07 | Dynogen Pharmaceuticals, Inc. | METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS |
| US7169812B2 (en) * | 2003-07-01 | 2007-01-30 | Medtronic, Inc. | Process for producing injectable gabapentin compositions |
| AU2004271800A1 (en) * | 2003-09-12 | 2005-03-24 | Pfizer Inc. | Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors |
| GB0322140D0 (en) * | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| WO2005041976A2 (en) * | 2003-10-23 | 2005-05-12 | Medtronic, Inc. | Injectable gabapentin compositions |
| EP2007723A2 (en) * | 2006-04-11 | 2008-12-31 | Novartis AG | Organic compounds |
| CN101610761A (zh) * | 2006-12-22 | 2009-12-23 | 诺瓦提斯公司 | 作为ddp-iv抑制剂的1-氨基甲基-l-苯基-环己烷衍生物 |
| CA2723358A1 (en) * | 2008-05-05 | 2009-11-12 | Allison B. Reiss | Method for improving cardiovascular risk profile of cox inhibitors |
| SI2331210T1 (sl) * | 2008-09-05 | 2014-10-30 | Gruenenthal Gmbh | Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika |
| KR102631399B1 (ko) * | 2018-03-30 | 2024-02-01 | 씨지인바이츠 주식회사 | 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물 |
| CA3200132A1 (en) * | 2020-10-28 | 2022-05-05 | Tremeau Pharmaceuticals, Inc. | Aqueous formulations of water insoluble cox-2 inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234929A (en) * | 1992-07-20 | 1993-08-10 | William Chelen | Method of treating motion sickness with anticonvulsants and antitussive agents |
| US5321012A (en) * | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
| US5420270A (en) * | 1993-10-07 | 1995-05-30 | G. D. Searle & Co. | Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
| US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US5352638A (en) * | 1994-02-22 | 1994-10-04 | Corning Incorporated | Nickel aluminosilicate glass-ceramics |
| HU0102041D0 (en) * | 1994-07-27 | 2001-07-30 | Warner Lambert Co | Pharmacological compounds which bind to [3h]-gabapentine binding protein |
| US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| WO1999008670A1 (en) * | 1997-08-20 | 1999-02-25 | Guglietta, Antonio | Gaba analogs to prevent and treat gastrointestinal damage |
| WO1999012537A1 (en) * | 1997-09-08 | 1999-03-18 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| IL135315A0 (en) * | 1997-12-16 | 2001-05-20 | Warner Lambert Co | 4(3)-substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
| CA2359485A1 (en) * | 1999-03-10 | 2000-09-14 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| HN2000000224A (es) * | 1999-10-20 | 2001-04-11 | Warner Lambert Co | Aminoacidos biciclicos como agentes farmaceuticos |
| GB9927844D0 (en) * | 1999-11-26 | 2000-01-26 | Glaxo Group Ltd | Chemical compounds |
| BR0008059A (pt) * | 1999-12-08 | 2002-03-26 | Pharmacia Corp | Composições de valdecoxib |
-
2003
- 2003-02-12 EP EP03742460A patent/EP1480639A1/en not_active Withdrawn
- 2003-02-12 MX MXPA04008175A patent/MXPA04008175A/es unknown
- 2003-02-12 RU RU2004125609/15A patent/RU2286151C2/ru not_active IP Right Cessation
- 2003-02-12 IL IL16293203A patent/IL162932A0/xx unknown
- 2003-02-12 CN CNA038043564A patent/CN1635887A/zh active Pending
- 2003-02-12 WO PCT/IB2003/000534 patent/WO2003070237A1/en not_active Ceased
- 2003-02-12 JP JP2003569193A patent/JP2005523281A/ja not_active Abandoned
- 2003-02-12 AU AU2003246864A patent/AU2003246864A1/en not_active Abandoned
- 2003-02-12 KR KR10-2004-7013032A patent/KR20040085216A/ko not_active Ceased
- 2003-02-12 PL PL03372210A patent/PL372210A1/xx not_active Application Discontinuation
- 2003-02-12 BR BR0307906-6A patent/BR0307906A/pt not_active IP Right Cessation
- 2003-02-12 CA CA002476438A patent/CA2476438A1/en not_active Abandoned
- 2003-02-14 US US10/366,798 patent/US20030199567A1/en not_active Abandoned
- 2003-02-17 PE PE2003000166A patent/PE20031052A1/es not_active Application Discontinuation
- 2003-02-19 UY UY27675A patent/UY27675A1/es not_active Application Discontinuation
- 2003-02-20 AR ARP030100547A patent/AR038531A1/es unknown
- 2003-02-21 HN HN2003000071A patent/HN2003000071A/es unknown
- 2003-02-21 TW TW092103596A patent/TW200303214A/zh unknown
- 2003-02-21 PA PA20038567201A patent/PA8567201A1/es unknown
-
2004
- 2004-08-13 CO CO04079024A patent/CO5611109A2/es not_active Application Discontinuation
- 2004-09-21 NO NO20043947A patent/NO20043947L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR038531A1 (es) | 2005-01-19 |
| UY27675A1 (es) | 2003-09-30 |
| CO5611109A2 (es) | 2006-02-28 |
| MXPA04008175A (es) | 2004-11-26 |
| PA8567201A1 (es) | 2003-11-12 |
| NO20043947L (no) | 2004-09-21 |
| TW200303214A (en) | 2003-09-01 |
| CN1635887A (zh) | 2005-07-06 |
| EP1480639A1 (en) | 2004-12-01 |
| AU2003246864A1 (en) | 2003-09-09 |
| WO2003070237A1 (en) | 2003-08-28 |
| HN2003000071A (es) | 2003-11-24 |
| PE20031052A1 (es) | 2003-12-24 |
| RU2004125609A (ru) | 2006-01-27 |
| RU2286151C2 (ru) | 2006-10-27 |
| PL372210A1 (en) | 2005-07-11 |
| BR0307906A (pt) | 2004-12-21 |
| KR20040085216A (ko) | 2004-10-07 |
| IL162932A0 (en) | 2005-11-20 |
| CA2476438A1 (en) | 2003-08-28 |
| US20030199567A1 (en) | 2003-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005523281A (ja) | アルファ−２−デルタリガンドとシクロオキシゲナーゼ−２の選択的阻害剤との組合せ | |
| WO2005002585A1 (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | |
| CA2345641A1 (en) | A method for treating inflammatory diseases by administering a thrombin inhibitor | |
| US20070203212A1 (en) | Method of treating osteoarthritis | |
| JP2007500690A (ja) | スタチンおよびエーテルを用いた炎症および炎症関連疾患の治療方法 | |
| AU2003255937A1 (en) | Method of treating osteoarthritis | |
| PT1799199E (pt) | Uso de inibidores da renina para a prevenção ou tratamento da disfunção diastólica ou insuficiência cardíaca diastólica | |
| JP2017533956A (ja) | 筋肉痛を含む病態の治療のための組合せ | |
| KR20080003429A (ko) | 비스테로이드 소염 약물 및 알파-델타-리간드의 상승작용적조합물 | |
| US20040034085A1 (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | |
| KR20080108156A (ko) | 유기 화합물의 조합물 | |
| JP2005534678A (ja) | 注意欠陥多動性障害の治療方法 | |
| US20050004196A1 (en) | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | |
| JP2005519098A (ja) | 変形性関節症の治療方法 | |
| JP2006502991A (ja) | マトリックスメタロプロテイナーゼ−１３のアロステリックアルキン阻害剤とセレコキシブまたはバルデコキシブではないシクロオキシゲナーゼ−２の選択的阻害剤との組合せ物 | |
| JP2006502114A (ja) | マトリクスメタロプロテイナーゼ−１３のアロステリックアルキン阻害薬とセレコキシブまたはバルデコキシブとの組合せ | |
| EP2258364A1 (en) | Preventive and/or remedy for vascular diseases | |
| EP3025717B1 (en) | Synergistic pharmaceutical composition of two analgesics having a distinct pharmacokinetic profile | |
| Kappel et al. | Prescribing Information Version 2.2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060209 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060209 |
|
| A762 | Written abandonment of application |
Free format text: JAPANESE INTERMEDIATE CODE: A762 Effective date: 20080304 |